Il-5rΑ×CD3Ε t cell engaging bispecific antibody and uses thereof

A T cell-engaging bispecific antibody targeting IL-5Rα and CD3ε, using heterodimeric heavy chain technology, addresses the challenges of eosinophil reduction in allergic and inflammatory diseases by inducing effective cytotoxicity against eosinophils, overcoming limitations of existing treatments.

WO2024228568A1PCT designated stage expired Publication Date: 2024-11-07AJOU UNIV IND ACADEMIC COOP FOUND
View PDF 8 Cites 0 Cited by

Patent Information

Application Number
PCT/KR2024/005975
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-03
Filing Date
2024-05-03
Publication Date
2024-11-07

AI Technical Summary

Technical Problem

Current treatments for allergic and inflammatory diseases associated with eosinophilic disorders, such as asthma, face limitations in effectively reducing eosinophil levels without increasing IL-5 serum levels or developing resistance, and existing bispecific antibodies have drawbacks in efficacy, toxicity, and serum half-life.

Method used

Development of a T cell-engaging bispecific antibody that simultaneously targets IL-5Rα and CD3ε, utilizing heterodimeric heavy chain constant region technology to enhance affinity and cytotoxicity, allowing for T cell-mediated reduction of eosinophils without elevating IL-5 levels and minimizing resistance.

Benefits of technology

The antibody effectively induces T cell-mediated cytotoxicity against eosinophils, achieving significant eosinophil reduction while avoiding the limitations of existing therapies, including reduced IL-5 serum levels and lower risk of resistance.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure KR2024005975_07112024_PF_FP_ABST
    Figure KR2024005975_07112024_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to a T cell engaging bispecific antibody. More particularly, the present invention relates to: a bispecific antibody that simultaneously binds to human interleukin-5 (IL-5) receptor alpha subunit (IL-5Rα), which is a receptor of human IL-5, and CD3ε, which is a human T cell marker; a nucleic acid encoding same; a vector comprising the nucleic acid; a cell transformed with the vector; a method for producing the bispecific antibody or; a composition comprising same for the prevention or treatment of allergic diseases, inflammatory diseases, and / or diseases caused by an increase in eosinophils; and a composition comprising same for the diagnosis of allergic diseases, inflammatory diseases, and / or diseases caused by an increase in eosinophils.
Need to check novelty before this filing date? Find Prior Art

Description

IL-5Rα×CD3ε T cell-engaging bispecific antibody and uses thereof

[0001] The present invention relates to a T cell engaging bispecific antibody. More specifically, the present invention relates to a bispecific antibody that simultaneously binds to human IL-5 receptor alpha subunit (IL-5Rα), which is a receptor for human interleukin-5 (IL-5), and CD3, which is a human T cell marker, a nucleic acid encoding the same, a vector comprising the nucleic acid, a cell transformed with the vector, the antibody or a method for producing the same, a composition comprising the same for preventing or treating an allergic disease, an inflammatory disease, and / or a disease caused by an increase in eosinophils, and a composition for diagnosing an allergic disease, an inflammatory disease, and / or a disease caused by an increase in eosinophils, and a composition for removing eosinophils by T cell engaging.

[0002]

[0003] Human interleukin 5 (hereinafter referred to as IL-5) is a type of cytokine secreted by T cells, mast cells, etc. IL-5 in mice is known to act as a differentiation and proliferation factor for B cells and eosinophils. In humans, it is known to act mainly as a differentiation and proliferation factor for eosinophils. The IL-5 receptor is composed of an α chain (hereinafter referred to as IL-5Rα) and a β chain (hereinafter referred to as IL-5Rβ or βc receptor). In addition, IL-5Rα is involved in direct binding to IL-5, and the βc receptor does not exhibit binding ability to IL-5 by itself, but is responsible for intracellular signal transduction. Additionally, it is known that the βc receptor acts as a common receptor with receptors such as interleukin-3 (hereinafter referred to as IL-3) and granulocyte colony-stimulating factor (hereinafter referred to as GM-CSF).

[0004] In humans, the IL-5 receptor is expressed on eosinophils, basophils, and mast cells. It is particularly overexpressed on eosinophils. IL-5 is important for eosinophil maturation, proliferation, and activation and can enhance basophil differentiation. IL-5 promotes eosinophil tissue accumulation through its ability to upregulate the expression of adhesion molecules during eosinophil migration to other tissues. Furthermore, IL-5 prolongs eosinophil survival by blocking apoptosis. The major cellular sources of IL-5 are type 2 helper T cells (Th2 cells), type 2 innate lymphoid cells (ILC2s), mast cells, and natural killer T cells.

[0005] Eosinophils are circulating granulocytes produced in the bone marrow and are a major cell type recruited to sites of inflammatory responses. Eosinophil counts are known to be elevated in the blood of patients with allergic diseases such as chronic bronchial asthma. Eosinophils release toxic granule proteins, reactive oxygen species (ROS), cytokines, and lipid mediators. Therefore, an increase in eosinophils is known to be involved in the pathogenesis of various inflammatory diseases, including allergic diseases associated with hypersensitivity reactions in lung tissue (Possa et al., 2013). The close association between eosinophils and IL-5 has led to the development of novel drugs that directly inhibit eosinophil activity by acting on IL-5 and IL-5Rα, thereby treating allergic diseases such as chronic bronchial asthma.

[0006] Mepolizumab is an N-glycosylated humanized IgG1 antibody that binds to IL-5 and inhibits its binding to IL-5Rα. Mepolizumab has been tested in several diseases, including severe asthma, atopic dermatitis, and nasal polyposis. In asthma, mepolizumab achieved favorable outcomes and was approved by the FDA in 2015. Eosinophil counts were found to decrease in mepolizumab-treated subjects, but serum IL-5 levels increased over time (Pouliquen et al., 2015; Tsukamoto et al., 2016). One group hypothesized that most of the IL-5 detected during treatment is part of a complex bound to immunoglobulin (mostly mepolizumab), extending the half-life of the complexed IL-5. The biological significance and fate of this complex remain unknown.

[0007] Reslizumab is a humanized IgG4 antibody that binds to IL-5 with high affinity and blocks its biological function. It is approved in the United States and Europe as add-on maintenance therapy in patients with severe eosinophilic asthma. Like mepolizumab, resilizumab increased serum IL-5 levels after 1 month of treatment in patients with hypereosinophilic syndrome (HES). However, it is still unknown whether this represents free or complexed IL-5. Culture medium-containing serum from resilizumab-treated patients has been shown to prolong eosinophil survival in vitro, leading researchers to hypothesize that anti-IL-5 agents not only extend half-life but may actually enhance IL-5 activity under certain conditions (Roufosse, 2018).

[0008] Benralizumab is an afucosylated humanized IgG1 antibody that targets IL-5Rα, and thus has two mechanisms of action that differ from anti-IL-5 antibodies. Benralizumab not only 1) inhibits cell growth by blocking the action of IL-5, but also 2) induces antibody-dependent cellular cytotoxicity (ADCC) in natural killer cells and macrophages. In addition, the afucosylated Fc enhances the affinity for FcγRIIIa expressed on the surface of natural killer (NK) cells and macrophages, resulting in an approximately 1,000-fold stronger ADCC effect. This dual mechanism of action of benralizumab induces a much more rapid and higher level of eosinophil depletion than that induced by other monoclonal antibodies targeting the IL-5 pathway, such as mepolizumab and recilizumab (Davila Gonzalez et al., 2019). Therefore, it has been proposed as a treatment not only for eosinophilic asthma but also for chronic obstructive pulmonary disease (COPD), eosinophilic syndromes, and chronic rhinitis.

[0009] According to studies reported to date, targeting IL-5Rα rather than IL-5 has the advantage of directly lowering eosinophil counts without increasing the half-life of IL-5. However, no therapeutic anti-IL-5Rα antibody other than benralizumab has yet been approved, and benralizumab has not shown a significant effect in some patients. In addition, there is a problem that resistance to the treatment may develop, such as the generation of anti-drug antibodies (ADAs) due to continuous and repeated administration of the same treatment. Therefore, 5R65.7, an anti-IL-5Rα antibody that targets an epitope in the membrane-proximal domain of IL-5Rα and has higher affinity, has been developed (Korean Patent Application No. 10-2020-0117668). However, when evaluating ADCC efficacy using eosinophils and PBMCs from patient blood samples, the problem was that only about 30% of all eosinophils exhibited cytotoxicity. Furthermore, previous studies have shown that eosinophil depletion does not increase the risk of parasitic infections or reduced vaccine responses (Manetz et al., 2021). Considering these findings, there remains a high demand for drugs that can induce more potent eosinophil reduction.

[0010] The mechanism of action of benralizumab and 5R65.7 is to selectively induce an immune response against the target, triggering the attack and subsequent destruction of the target cell by natural killer (NK) cells, which are immune effector cells. Meanwhile, T cells, although there are several subsets of T cells with distinct functions, cytotoxic T lymphocytes (CTLs) constitute the most potent effector cells of the immune system, but they cannot be activated by effector mechanisms mediated by the Fc domain of conventional therapeutic antibodies. T cells can be distinguished from other lymphocytes, such as NK cells and B cells, by the presence of the T cell receptor (TCR) on their cell surface. The TCR binds to major histocompatibility complex (MHC) molecules and results in antigen recognition, consisting of two different protein chains. In 95% of T cells, the TCR consists of an alpha (α) and a beta (β) chain. When the TCR engages an antigenic peptide and MHC (peptide / MHC complex), the T lymphocyte is activated through a series of biochemical events mediated by associated enzymes, co-receptors, specialized adaptor molecules, and activated or released transcription factors.

[0011] The CD3 receptor complex is a protein complex composed of four chains. In mammals, the complex comprises a CD3γ (gamma) chain, a CD3δ (delta) chain, and two CD3ε (epsilon) chains. These chains associate with the T-cell receptor (TCR) and the so-called ζ (zeta) chain to form the T-cell receptor-CD3 complex and generate an activation signal in T lymphocytes. The CD3γ (gamma), CD3δ (delta), and CD3ε (epsilon) chains are highly related cell surface proteins of the immunoglobulin superfamily that contain a single extracellular immunoglobulin domain. The intracellular tail of the CD3 molecule contains a single conserved motif, known as the immunoreceptor tyrosine-based motif for shortening, or ITAM, which is essential for the signaling capacity of the TCR. The CD3ε molecule is a polypeptide encoded in humans by the CD3E gene, which is located on chromosome 11. The most preferred epitope of CD3ε is contained within amino acid residues 1 to 27 of the human CD3 epsilon extracellular domain.

[0012] Therefore, in relation to this, it is a T cell engaging bispecific antibody that recruits T cells to the target cells as a mechanism for inducing a decrease in target cells in the body, forms a cytolytic synapse between the T cells and the target cells, and induces the T cells to kill the target cells without going through the activation step using the protein major histocompatibility complex (MHC).

[0013] Research on bispecific antibodies that induce cytotoxicity by targeting only cells expressing cancer-specific biomarkers or overexpressing specific biomarkers among various cell types has been ongoing, utilizing T cells, the most powerful immune system in the body. Several dual T cell-engaging bispecific antibody formats have been developed, mainly in the field of cancer immunotherapy, and their suitability for T cell-mediated cancer immunotherapy has been studied. Among these, so-called BiTE (bispecific T cell engager) molecules are very well characterized and have already shown some promising results in the clinic (Nagorsen, D. and PA Baeuerle (2011). "Immunomodμlatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab." Exp Cell Res 317(9): 1255-1260.). BiTEs are tandem scFv molecules, in which two scFv molecules are fused by a flexible linker. A representative example is bilnatumomab, a CD19×CD3 BiTE used for the treatment of refractory acute lymphoblastic leukemia. During clinical trials, it demonstrated higher cytotoxicity at much lower concentrations than existing anti-CD19 monoclonal antibodies, leading to FDA approval in 2014. Additional bispecific formats being evaluated for T cell engagement include diabodies (Holliger, P., et al. (1996). "Specific killing of lymphoma cells by cytotoxic T-cells mediated by a bispecific diabody." Protein Engineering, Design and Selection 9(3): 299-305.) and their derivatives, such as tandem diabodies (Kipriyanov, S. M., et al. (1999)."Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics." J Mol Biol 293(1): 41-56.) A more recent development is the so-called DART (dual affinity retargeting) molecule, which is based on the diabody format but features a C-terminal disulfide (SS) bond for additional stabilization (Moore, PA, et al. (2011). "Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma." Blood 117(17): 4542-4551.). The so-called triomab, a full hybrid mouse / rat IgG molecule currently being evaluated in clinical trials, represents a larger format. (Seimetz, D., et al. (2010). "Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM×anti-CD3) as a targeted cancer immunotherapy." Cancer Treatment Reviews 36(6): 458-467.). In addition, the development and clinical trials of several bispecific antibodies that simultaneously target CD3 and biomarkers that are specific to cancer cells or overexpressed compared to normal cells, such as CD20, BCMA, CEA, Mesothelin, and ROR1, are ongoing to induce a mechanism to eliminate cancer cells using T cells (Qi, J., et al. (2018).“Potent and selective antitumor activity of a T cell-engaging bispecific antibody targeting a membrane-proximal epitope of ROR1.” Proc Natl Acad Sci USA 115(24): E5467-e5476.).

[0014] However, known bispecific antibodies, such as BiTEs, diabodies, and DARTs, have major drawbacks in their efficacy, toxicity, and availability. Molecules lacking an Fc domain of less than 70 kDa, such as BiTEs, diabodies, and DARTs, can efficiently cross-link effector cells and target cells, but have very short serum half-lives, necessitating continuous infusion into patients. On the other hand, T-cell-engaging bispecific antibodies containing Fc have larger molecular weights (>100 kDa), making cross-linking effector cells more difficult than bispecific antibodies lacking an Fc domain. This may result in reduced T-cell-mediated cytotoxicity induction. However, they offer the advantages of a longer half-life and simpler protein production and purification processes compared to Fc-deficient bispecific antibodies. Meanwhile, there is currently no progress in developing bispecific antibodies that target cells that are involved in immune responses other than cancer cells and that cause inflammatory and allergic reactions within the body.

[0015] Against this technical background, the inventors of the present application sought to develop a T cell-engaging bispecific antibody that simultaneously targets IL-5Rα, which is overexpressed in eosinophils of patients with eosinophilic asthma, and the ε domain of CD3, a T cell marker, to induce eosinophilia reduction mediated by T cells. In the present invention, 5R65.7 antibody, which targets an epitope of the membrane-proximal domain of IL-5Rα with higher affinity than the existing benralizumab antibody, and humanized SP34 antibody, which is a humanized mouse antibody targeting the ε domain of CD3, were used to construct eight formats of IL-5Rα×CD3ε T cell-engaging bispecific antibodies, and which format exhibited the highest T cell-mediated cytotoxicity induction ability.

[0016] Meanwhile, to produce a T cell-engaging bispecific antibody containing Fc, the heterodimeric heavy chain constant region (heterodimeric Fc) technology was used. The heterodimeric heavy chain constant region (heterodimeric Fc) technology is a technology that forms a heavy chain constant region in a heterodimer form by engineering the interaction surface between the last domains of the constant region, which greatly contributes to the homodimerization of naturally occurring antibodies (IgG, IgM, IgA, IgD, IgE), to have a bond that favors heterodimerization and disfavors or repel homodimerization through specific non-covalent bonds. More specifically, it induces mutations in the CH3 domains of two different antibody heavy chains through genetic engineering, so that the two heavy chains form a heterodimer while having very similar structures to naturally occurring antibodies and minimal deviations in sequence. Among them, the EW-RVT heterodimeric Fc mutant used in the present invention is a mutant that promotes the formation of a heterodimer by forming a selective electrostatic bond at the CH3 domain interaction surface (K360ECH3A-Q347RCH3B) and forming a complementary hydrophobic bond instead of the existing electrostatic bond (K409WCH3A-D399VCH3B / F405TCH3B) through a new mutation strategy by analyzing the interaction of the existing mutants in terms of sequence and structure (US Patent No. 9,951,145; Republic of Korea Patent No. 1,522,954; Choi HJ et al. Molecular Cancer Therapeutics, 2013;12(12): 2748-2759). It was confirmed that the IL-5Rα×CD3ε T cell-engaging bispecific antibody manufactured in this way showed superior T cell activation ability and T cell-mediated cytotoxicity compared to the negative control and the benralizumab control, a T cell-engaging bispecific antibody manufactured using benralizumab, when in the same format.

[0017]

[0018] Summary of the invention

[0019] The purpose of the present invention is to provide a bispecific antibody that targets IL-5Rα and binds to eosinophils and basophils expressing IL-5Rα, while simultaneously targeting CD3 and binding to T cells expressing CD3, thereby inducing T cell mediated cytotoxicity.

[0020] The purpose of the present invention is to provide a bispecific antibody using a humanized antibody that strongly induces T cell mediated cytotoxicity against eosinophils and basophils expressing IL-5Rα by using a 5R65.7 antibody fragment that binds to IL-5Rα with high affinity and has a membrane-proximal domain as an epitope.

[0021] The purpose of the present invention is to produce a bispecific antibody against 5R65.7, an anti-IL-5Rα human antibody, and SP34, an anti-CD3ε mouse antibody, by referring to existing literature and replacing the CDR amino acid sequence of the most similar human embryonic antibody sequence with the CDR sequence of mouse SP34 to produce a partially humanized SP34 (Korean Patent Registration No. 10-1973060), and then introducing heterodimeric heavy chain constant region Fc technology to provide a bispecific antibody constructed therefrom or a nucleic acid encoding the same.

[0022] Another object of the present invention is to provide a vector containing the nucleic acid, a cell transformed with the vector, and a method for producing the same.

[0023] Another object of the present invention is to provide a pharmaceutical composition for preventing or treating allergic diseases, inflammatory diseases, and / or diseases caused by an increase in eosinophils, comprising the above-described bispecific antibody.

[0024] Another object of the present invention is to provide a composition for removing eosinophils comprising the above-described bispecific antibody or an antigen-binding fragment thereof.

[0025] Another object of the present invention is to provide a composition for diagnosing allergic diseases, inflammatory diseases and / or diseases caused by an increase in eosinophils, comprising the above-described bispecific antibody.

[0026] To solve the above problem, the present invention provides eight formats of T cell engaging bispecific antibodies using antibodies or antigen-binding fragments thereof that bind to human IL-5Rα and recognize as an epitope one or more amino acid residues selected from the group consisting of amino acid residues 221 to 322 corresponding to domain 3 (D3) of the sequence of human IL-5 receptor alpha subunit (IL-5Rα).

[0027] The present invention provides eight formats of T cell engaging bispecific antibodies using SP34 antibody or antigen-binding fragment thereof that binds to human CD3ε and recognizes as an epitope one or more amino acid residues selected from the group consisting of amino acid residues 23 to 126 corresponding to the extracellular domain of the sequence of previously invented human CD3ε.

[0028] The present invention provides a bispecific antibody or antigen-binding fragment thereof that binds to IL-5Rα and CD3α, comprising an antibody or antigen-binding fragment thereof that binds to interleukin (IL)-5 receptor α (IL-5Rα) and an antibody or antigen-binding fragment thereof that binds to CD3α.

[0029] The present invention provides a bispecific antibody constructed using a previously invented CD3-activating agonist antibody.

[0030] The present invention provides a bispecific antibody comprising an antibody 5R65.7 targeting IL-5Rα paired with a previously invented CD3-activating agonist antibody.

[0031] The present invention provides a method for inducing T cell-mediated cytotoxicity against IL-5Rα expressing cells.

[0032] The present invention provides a method for inducing T cell-mediated cytotoxicity using a bispecific antibody comprising an antibody targeting IL-5Rα paired with an agonist antibody that activates CD3.

[0033] The present invention provides a method for treating eosinophilic asthma using a bispecific antibody comprising an antibody to IL-5Rα paired with an agonist antibody that activates CD3.

[0034] The present invention provides a molecule in which each domain is connected to each other via a peptide linker.

[0035] The present invention also relates to a nucleic acid encoding the bispecific antibody or an antigen-binding fragment thereof and an expression vector comprising such a nucleic acid.

[0036] The present invention also relates to a cell transformed with the expression vector.

[0037] The present invention also relates to a method for producing a bispecific antibody that simultaneously binds to human IL-5Rα and human CD3ε.

[0038] The present invention also relates to a conjugate comprising the bispecific antibody and a drug.

[0039] The present invention also relates to a composition for preventing or treating allergic diseases, inflammatory diseases, and / or diseases caused by an increase in eosinophils, comprising the bispecific antibody or an antigen-binding fragment thereof. The present invention also relates to a method for preventing or treating allergic diseases, inflammatory diseases, and / or diseases caused by an increase in eosinophils, comprising a step of administering the bispecific antibody or an antigen-binding fragment thereof to a patient. The present invention also relates to the use of the bispecific antibody or an antigen-binding fragment thereof in the manufacture of a composition for preventing or treating allergic diseases, inflammatory diseases, and / or diseases caused by an increase in eosinophils.

[0040] The present invention also relates to a composition for removing eosinophils, comprising the bispecific antibody or an antigen-binding fragment thereof. The present invention also relates to a method for removing eosinophils, comprising the step of administering the bispecific antibody or an antigen-binding fragment thereof to a subject. The present invention also relates to the use of the bispecific antibody or an antigen-binding fragment thereof in the manufacture of a composition for removing eosinophils.

[0041] The present invention also relates to a composition for diagnosing allergic diseases, inflammatory diseases and / or diseases caused by an increase in eosinophils, comprising the above-described bispecific antibody or an antigen-binding fragment thereof.

[0042]

[0043] Figure 1 shows a schematic diagram of eight different formats of IL-5Rα×CD3ε T cell engaging bispecific antibodies, along with the nomenclature according to the format, the predicted molecular weight, and the expression level of each bispecific antibody produced by the method described in Example 2. Figure C H 3 (EW) is CH3A (EW), C after this description H 3 (RVT) is referred to as CH3B (RVT) from this description onwards.

[0044] Figure 1a shows a schematic diagram of recombinant expression vectors for expressing IL-5Rα×CD3ε-Diabody-Fc. L represents a peptide linker of the GGGSGGGG sequence composed of amino acids Glycine and Serine, and *H represents a hinge of the GCPPCP sequence composed of amino acids Glycine, Cysteine, and Proline, which is not a hinge sequence of the general IgG1 subclass.

[0045] Figure 2b shows a schematic diagram of recombinant expression vectors for expressing IL-5Rα×CD3ε-scFv(L) / scFv-Fc. L represents a peptide linker of the sequence GGGGSGGGGSGGGGS (hereinafter referred to as (G4S)3) composed of amino acids Glycine and Serine, and H represents a hinge sequence of a typical IgG1 subclass.

[0046] Figure 2c shows a schematic diagram of recombinant expression vectors for expressing IL-5Rα×CD3ε-scFv(H) / scFv-Fc. L represents a peptide linker of the (G4S)3 sequence composed of amino acids Glycine and Serine, and H represents a hinge sequence of a typical IgG1 subclass.

[0047] Figure 2d shows a schematic diagram of recombinant expression vectors for expressing IL-5Rα×CD3ε-BiTE Fc. Bold L represents a (G4S)3 peptide linker composed of amino acids Glycine and Serine, and thin L represents a GGGGS (hereinafter referred to as G4S) peptide linker composed of amino acids Glycine and Serine. H represents the hinge sequence of the typical IgG1 subclass.

[0048] Figure 2e shows a schematic diagram of recombinant expression vectors for expressing IL-5Rα×CD3ε-scFv / Fab-Fc. L represents a (G4S)3 peptide linker composed of the amino acids Glycine and Serine. H represents the hinge sequence of the typical IgG1 subclass.

[0049] Figure 2f shows a schematic of recombinant expression vectors for expressing IL-5Rα×CD3ε-IgG analogs. H represents the hinge sequence of the common IgG1 subclass. The SP34 heavy and light chains and the 5R65.7 heavy and light chains contain complementary mutations in the CH1 and CL regions to prevent cross-linking.

[0050] Figure 2g shows a schematic diagram of recombinant expression vectors for expressing IL-5Rα×CD3ε-BiTE(L) / scFv-Fc. Bold L represents a (G4S)3 peptide linker composed of amino acids Glycine and Serine, and thin L represents a G4S peptide linker composed of amino acids Glycine and Serine. H represents the hinge sequence of a typical IgG1 subclass.

[0051] Figure 2h shows a schematic diagram of recombinant expression vectors for expressing IL-5Rα×CD3ε-BiTE(H) / scFv-Fc. Bold L represents a (G4S)3 peptide linker composed of amino acids Glycine and Serine, and thin L represents a G4S peptide linker composed of amino acids Glycine and Serine. H represents the hinge of the GCPPCP sequence.

[0052] Figure 2i shows a schematic of a recombinant expression vector for expressing HER2×CD3ε-IgG analogs. The SP34 heavy and light chains and the Trastuzumab heavy and light chains contain complementary mutations in the CH1 and CL regions to prevent cross-linking.

[0053] Figure 3a shows the results of transient expression and purification of the IL-5Rα×CD3ε T cell-engaging bispecific antibodies in the eight formats specified by co-transfection into HEK293F cells, followed by separation of 3 μg of protein on 12% SDS-PAGE under non-reducing and reducing conditions, and analysis of size and composition by Coomasie Blue staining. Non-reducing refers to non-reducing conditions, Reducing refers to reducing conditions, and M is a protein marker. The red-colored part in the non-reducing condition results indicates the bands corresponding to the sizes of the IL-5Rα×CD3ε T cell-engaging bispecific antibodies from 1 to 8.

[0054] Figure 3b shows the results of size exclusion chromatography (SEC) analysis of the IL-5Rα×CD3ε T cell-engaging bispecific antibodies in the specified eight formats. In the SEC analysis, the running buffer was 1× PBS (pH 7.4, 12 mM phosphate, 137 mM NaCl, 2.7 mM KCl), the flow rate was 0.75 ml / min, and the protein input was 20 μg (20 μl injection at 1 mg / ml).

[0055] Figure 4 shows the IL-5Rα×CD3ε T cell engaging bispecific antibodies in four formats (Diabody-Fc, scFv(L) / scFv-Fc, IgG analog, BiTE(L) / scFv-Fc) selected after physical property evaluation on K562 / IL-5Rα cell line expressing human IL-5Rα, activated PBMC expressing human CD3ε, and wild type K562 (WT K562) cell line expressing neither IL-5Rα nor CD3ε, at concentrations of 50 nM (for K562 / IL-5Rα, WT K562) and 5 nM (for activated PBMC), followed by treatment with Alexa Flour 647 AFFINIPURE Goat Anti-human IgG, Fcγ fragment specific 2 nd The fluorescence intensity was measured using a FACS calibur after fluorescent labeling with antibody (Jacksonimmunology, 109-605-098).

[0056] Figure 5a shows binding isotherms analyzing the affinity of IL-5Rα×CD3ε T cell engaging bispecific antibodies of four formats (Diabody-Fc, scFv(L) / scFv-Fc, IgG analog, BiTE(L) / scFv-Fc) selected after property evaluation for IL-5Rα and CD3ε.

[0057] Figure 5b shows binding isotherms analyzed to determine whether simultaneous binding to IL-5Rα and CD3ε is possible for IL-5Rα×CD3ε T cell-engaging bispecific antibodies of four formats (Diabody-Fc, scFv(L) / scFv-Fc, IgG analog, BiTE(L) / scFv-Fc) selected after property evaluation.

[0058] Figure 6a shows the results of evaluating the T cell-mediated cytotoxicity induction ability of four formats of IL-5Rα×CD3ε T cell-engaging bispecific antibodies using K562 / IL-5Rα, a cell line expressing human IL-5Rα, and activated T cells under conditions of an effector cell to target cell ratio of 5:1 and 24-hour incubation.

[0059] Figure 6b shows the results of evaluating the T cell-mediated cytotoxicity induction ability of four formats of IL-5Rα×CD3ε T cell-engaging bispecific antibodies using wild-type K562 cells and activated T cells.

[0060] Figure 7 shows the results of quantifying the amount of IFN-γ present in the culture medium using ELISA after the T cell-mediated cytotoxicity induction evaluation experiment.

[0061] Figure 8 shows the results of analyzing the expression of IL-5Rα in eosinophils (Siglec-8 expressing cells) and neutrophils (Siglec-8 non-expressing cells) in the granulocyte layer (including eosinophils and neutrophils) isolated from the peripheral blood of healthy donors (Healthy controls) using FACS Calibur.

[0062] Figure 9 shows the results of analyzing the expression of IL-5Rα in eosinophils (Siglec-8 expressing cells) and neutrophils (Siglec-8 non-expressing cells) in the granulocyte layer (including eosinophils and neutrophils) isolated from the peripheral blood of patients with severe eosinophilic asthma (SEA) using FACS Calibur.

[0063] Figure 10 shows the results showing the percentage of eosinophils in the granulocyte layer (including eosinophils and neutrophils) isolated from the peripheral blood of healthy donors and patients with severe asthma.

[0064] Figure 11a shows a schematic diagram of recombinant expression vectors for expressing IL-5Rα(ben)×CD3ε-scFv(L) / scFv-Fc. L represents a peptide linker of the sequence GGGGSGGGGSGGGGS (hereinafter referred to as (G4S)3) composed of amino acids Glycine and Serine, and H represents a hinge sequence of a typical IgG1 subclass.

[0065] Figure 11b shows a schematic diagram of recombinant expression vectors for expressing IL-5Rα(5R65)×CD3ε-scFv(L) / scFv-Fc. L represents a peptide linker of the sequence GGGGSGGGGSGGGGS (hereinafter referred to as (G4S)3) composed of amino acids Glycine and Serine, and H represents a hinge sequence of a typical IgG1 subclass.

[0066] Figure 11c shows a schematic diagram of recombinant expression vectors for expressing HER2×CD3ε-scFv(L) / scFv-Fc. L represents a peptide linker of the sequence GGGGSGGGGSGGGGS (hereinafter referred to as (G4S)3) composed of amino acids Glycine and Serine, and H represents a hinge sequence of a typical IgG1 subclass.

[0067] Figure 12a shows a schematic diagram of three control T cell engaging bispecific antibodies in the IL-5Rα×CD3ε-scFv(L) / scFv-Fc format, along with the nomenclature according to the format, the predicted molecular weight, and the expression level of each bispecific antibody produced by the method described in Example 2.

[0068] Figure 12b shows the results of transiently expressing and purifying three types of control T cell-engaging bispecific antibodies of the IL-5Rα×CD3ε-scFv(L) / scFv-Fc format into HEK293F cells through co-transfection, and then separating 3 μg of protein on 12% SDS-PAGE under non-reducing and reducing conditions, and analyzing the size and assembly form through Coomasie Blue staining. Non-reducing means non-reducing condition, Reducing means reducing condition, and M is a protein marker.

[0069] Figure 12c shows the results of size exclusion chromatography (SEC) analysis of three control T cell-engaging bispecific antibodies of the IL-5Rα×CD3ε-scFv(L) / scFv-Fc format. In the SEC analysis, the running buffer was 1× PBS (pH 7.4, 12 mM phosphate, 137 mM NaCl, 2.7 mM KCl), the flow rate was 0.75 ml / min, and the protein input was 20 μg (20 μl injection at 1 mg / ml).

[0070] Figure 13 shows the results of the treatment of K562 / IL-5Rα cell line expressing human IL-5Rα, activated PBMC expressing human CD3ε, and wild type K562 (WT K562) cell line expressing neither IL-5Rα nor CD3ε with IL-5Rα×CD3ε-scFv(L) / scFv-Fc and three control T cell engaging bispecific antibodies at concentrations of 50 nM (for K562 / IL-5Rα, WT K562) and 5 nM (for activated PBMC), followed by Alexa Flour 647 AFFINIPURE Goat Anti-human IgG, Fcγ fragment specific 2 ndThe fluorescence intensity was measured using a FACS calibur after fluorescent labeling with antibody (Jacksonimmunology, 109-605-098).

[0071] Figure 14a shows the results of evaluating the T cell-mediated cytotoxicity induction ability of three types of T cell-engaged bispecific antibodies in the IL-5Rα×CD3ε-scFv(L) / scFv-Fc format and control T cell-engaged bispecific antibodies using K562 / IL-5Rα, a cell line expressing human IL-5Rα, and activated T cells, under conditions of an effector cell to target cell ratio of 5:1 and 24-hour incubation.

[0072] Figure 14b shows the results of evaluating the T cell-mediated cytotoxicity induction ability of three types of T cell-engaged bispecific antibodies in the IL-5Rα×CD3ε-scFv(L) / scFv-Fc format and control T cell-engaged bispecific antibodies using K562 / IL-5Rα, a cell line expressing human IL-5Rα, and activated T cells, at an effector cell to target cell ratio of 10:1 and under 24-hour incubation conditions.

[0073] Figure 14c shows the results of evaluating the T cell-mediated cytotoxicity induction ability of three types of T cell-engaged bispecific antibodies in the IL-5Rα×CD3ε-scFv(L) / scFv-Fc format and control T cell-engaged bispecific antibodies using K562 / IL-5Rα, a cell line expressing human IL-5Rα, and activated T cells, under conditions of an effector cell to target cell ratio of 10:1 and 12 hours of incubation.

[0074] Figure 15 shows the results of evaluating the T cell-mediated cytotoxicity induction ability of three types of T cell-engaging bispecific antibodies of the IL-5Rα×CD3ε-scFv(L) / scFv-Fc format and control T cell-engaging bispecific antibodies using eosinophils and autologous activated T cells isolated from blood samples of five healthy donors, at an effector cell to target cell ratio of 5:1 and under 24-hour incubation conditions.

[0075] Figure 16 illustrates the use of the IL-5Rα×CD3ε bispecific antibody according to the present invention.

[0076]

[0077] Detailed description of the invention and preferred embodiments

[0078] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. In general, the nomenclature used herein is well known and commonly used in the art.

[0079] In addition, in an embodiment of the present invention, a K562 / IL-5Rα cell line stably expressing IL-5Rα was constructed using a lentivirus system, and the biological activity of an anti-IL-5Rα humanized antibody was evaluated.

[0080] To further increase the efficiency of eosinophil reduction, we sought to utilize T cells, the most potent effector cells in the body, and produced T cell-engaging bispecific antibodies, providing eight types of IL-5Rα×CD3ε T cell-engaging bispecific antibodies.

[0081] The T cell-mediated cytotoxicity of eight IL-5Rα×CD3ε T cell-engaging bispecific antibodies was evaluated using the K562 / IL-5Rα cell line described above and eosinophils derived from healthy donors and asthma patients.

[0082] Based on this, the present inventors provide eight types of IL-5Rα×CD3ε T cell-engaging bispecific antibodies that induce eosinophilia reduction in the body using T cells, the most potent effector cells in the body.

[0083] Accordingly, the present invention relates to a bispecific antibody that recognizes as an epitope at least one amino acid residue selected from the group consisting of amino acid residues 221 to 322 corresponding to domain 3 (D3) of the sequence of human IL-5 receptor alpha subunit (IL-5Rα) and at the same time recognizes as an epitope at least one amino acid residue selected from the group consisting of amino acid residues 23 to 126 corresponding to the extracellular domain of the sequence of human CD3ε.

[0084] The present invention relates to a bispecific antibody or antigen-binding fragment thereof that binds to interleukin (IL)-5 receptor α (IL-5Rα) and CD3α, comprising an antibody or antigen-binding fragment thereof that binds to IL-5Rα and an antibody or antigen-binding fragment thereof that binds to CD3α.

[0085] In an embodiment of the present invention, a bispecific antibody according to the present invention competitively binds to human interleukin-5 (IL-5) and IL-5Rα, and can simultaneously bind to an epitope comprising at least one amino acid residue selected from the group consisting of amino acid residues 221 to 322 corresponding to domain 3 (D3) of the sequence of human IL-5 receptor alpha subunit (IL-5Rα) and at least one amino acid residue selected from the group consisting of amino acid residues 23 to 126 corresponding to the extracellular domain of the sequence of human CD3ε.

[0086] The term "patient" as used herein refers to any single animal, more preferably a mammal (including non-human animals such as dogs, cats, horses, rabbits, zoo animals, cows, pigs, sheep, and non-human primates) in need of treatment. Most preferably, the patient herein is a human. In one embodiment, the "subject" of diagnosis or treatment is a prokaryotic or eukaryotic cell, tissue culture, tissue, or animal, e.g., a mammal, including a human.

[0087] The term "recombinant" as used herein refers to a polypeptide or polynucleotide that can be produced by combining polynucleotides or polypeptides in arrangements that do not exist in nature and do not normally occur together. The term may refer to a polypeptide produced via a biological host selected from a mammalian expression system, an insect cell expression system, a yeast expression system, and a bacterial expression system.

[0088] An "epitope" is a protein determinant to which an antibody can specifically bind. Epitopes typically consist of chemically active surface molecules, such as amino acids or sugar side chains, and typically have specific three-dimensional structural features as well as specific charge characteristics. Conformational and non-conformational epitopes are distinguished by the fact that binding to the former is lost in the presence of denaturing solvents, while binding to the latter is not.

[0089] The eight IL-5Rα×CD3ε T cell-engaging bispecific antibodies described in the present invention are characterized by having T cell-mediated cytotoxicity and mediating the death of cells expressing IL-5Rα.

[0090] The antibody according to the present invention provides a composition and method for treating diseases associated with IL-5 activity, such as allergic diseases. The composition relates to a bispecific antibody that recognizes an epitope in the extracellular domain of the human IL-5 receptor (IL-5Rα). The antibody has the ability to inhibit the biological activity of IL-5 and induces the death of cells (e.g., eosinophils) expressing IL-5Rα. Therefore, the present invention can be used for the diagnosis and treatment of allergic diseases such as chronic bronchial asthma and atopic dermatitis.

[0091]

[0092] The present invention relates to a bispecific antibody that simultaneously binds to human IL-5 receptor alpha subunit (IL-5Rα) and human CD3ε, produced by co-transformation with a nucleic acid encoding at least two sequences from SEQ ID NO: 33 to SEQ ID NO: 51.

[0093] The antibody or antigen-binding fragment thereof that binds to the IL-5Rα comprises a heavy chain CDR1 of SEQ ID NO: 1, a heavy chain CDR2 of SEQ ID NO: 2, a heavy chain CDR3 of SEQ ID NO: 3, and a light chain CDR1 of SEQ ID NO: 4; a light chain CDR2 of SEQ ID NO: 5; and a light chain CDR3 of SEQ ID NO: 6.

[0094] The antibody or antigen-binding fragment thereof that binds to the CD3α may comprise a heavy chain CDR1 of SEQ ID NO: 7, a heavy chain CDR2 of SEQ ID NO: 8, a heavy chain CDR3 of SEQ ID NO: 9, and a light chain CDR1 of SEQ ID NO: 10; a light chain CDR2 of SEQ ID NO: 11; and a light chain CDR3 of SEQ ID NO: 12.

[0095] As used herein, the term "IL-5Rα×CD3ε T cell engaging bispecific antibody, bispecific antibody" refers to an antibody that specifically binds to human IL-5Rα and CD3ε simultaneously. Specifically, it is preferably a form that does not exist naturally and is manufactured by genetic engineering or any method. The "bispecific antibody" of the present invention may be used interchangeably with "bitargeting antibody", "bispecific antibody" or "bispecific antibody protein". The bispecific antibody refers to a molecule whose antigen binding sites are linked directly or through a linker or can form a heterodimer by electrostatic interaction. The scope of the present invention includes not only the eight formats mentioned, but also all formats of bispecific antibodies that can be constructed including the complementarity-determining region (CDR) of the anti-IL-5Rα antibody 5R65.7 and the anti-CD3ε antibody SP34.

[0096] The bispecific antibody of the present invention is a structure in which proteins composed of variable and constant region domains of two to four antibodies are combined, and each combined protein is linked by a disulfide (disulfide, SS) bond.

[0097] As used herein, the term "heavy chain" refers to a full-length heavy chain and fragments thereof, which comprises a variable domain VH comprising an amino acid sequence having sufficient variable region sequence to confer specificity to an antigen, and three constant region domains CH1, CH2, and CH3. In addition, the term "light chain" as used herein refers to a full-length light chain and fragments thereof, which comprises a variable domain VL comprising an amino acid sequence having sufficient variable region sequence to confer specificity to an antigen, and a constant region domain CL.

[0098] The antibody or antigen-binding fragment thereof that binds to the IL-5Rα comprises a heavy chain variable region of SEQ ID NO: 20 and a light chain variable region of SEQ ID NO: 21, a heavy chain variable region of SEQ ID NO: 22 and a light chain variable region of SEQ ID NO: 23, or a heavy chain variable region of SEQ ID NO: 24 and a light chain variable region of SEQ ID NO: 21.

[0099] The antibody or antigen-binding fragment thereof that binds to the above CD3α may comprise a heavy chain variable region of SEQ ID NO: 25 and a light chain variable region of SEQ ID NO: 26.

[0100]

[0101] The above-mentioned total bispecific antibodies include subtypes of IgA, IgD, IgE, IgM and IgG, and in particular, IgG includes IgG1, IgG2, IgG3 and IgG4. The heavy chain constant region has gamma (γ), mu (μ), alpha (α), delta (δ) and epsilon (ε) types, and has subclasses of gamma1 (γ1), gamma2 (γ2), gamma3 (γ3), gamma4 (γ4), alpha1 (α1) and alpha2 (α2). The light chain constant region has kappa (κ) and lambda (λ) types.

[0102] Antigen-binding fragments of antibodies, or antibody fragments, refer to fragments that possess antigen-binding function, and include Fab, F(ab'), F(ab')2, and Fv. Among antibody fragments, Fab has a structure with variable regions of the light and heavy chains, a constant region of the light chain, and the first constant region (CH1) of the heavy chain, and has one antigen-binding site. Fab' differs from Fab in that it has a hinge region containing one or more cysteine ​​residues at the C-terminus of the heavy chain CH1 domain. F(ab')2 is generated when the cysteine ​​residues in the hinge region of Fab' form a disulfide bond.

[0103] Fv is the smallest antibody fragment that contains only the heavy chain variable region and the light chain variable region. A two-chain Fv has a heavy chain variable region and a light chain variable region non-covalently linked, and a single-chain Fv (scFv) has a heavy chain variable region and a light chain variable region covalently linked, usually via a peptide linker, or directly linked at the C-terminus, so that it can form a dimer-like structure like a two-chain Fv. These antibody fragments can be produced using proteolytic enzymes (for example, restriction digestion of a complete antibody with papain yields Fab, and digestion with pepsin yields F(ab')2) or using genetic recombination technology.

[0104] An "Fv" fragment is an antibody fragment containing the complete antibody recognition and binding site. This region is a dimer composed of one heavy chain variable domain and one light chain variable domain.

[0105] The "Fab" fragment comprises the variable and constant domains of the light chain and the variable and first constant domain (CH1) of the heavy chain. An F(ab')2 antibody fragment typically comprises a pair of Fab' fragments covalently linked by cysteines in the hinge region at the C-terminus of the Fab' fragment.

[0106] A "single-chain Fv (scFv)" antibody fragment is a construct consisting of a single polypeptide chain comprising the VH and VL domains of an antibody. The scFv may additionally comprise a polypeptide linker between the VH and VL domains that allows it to form the desired structure for antigen binding.

[0107] In one embodiment, the bispecific antibodies of the present invention include, but are not limited to, multispecific antibodies, human antibodies, humanized antibodies, modified antibodies, scFvs, Fab fragments, F(ab')2 fragments, disulfide-linked Fvs (sdFvs) and anti-idiotypic (anti-Id) antibodies, or epitope-binding fragments of the foregoing antibodies.

[0108] The heavy chain constant region can be selected from any one of the gamma (γ), mu (μ), alpha (α), delta (δ), or epsilon (ε) isotypes. For example, the constant region is gamma 1 (IgG1), gamma 2 (IgG2), gamma 3 (IgG3), or gamma 4 (IgG4). The light chain constant region can be kappa or lambda type.

[0109] The above bispecific antibody may comprise one or more selected from the group consisting of, but is not limited to:

[0110] Diabodies of antibodies that bind to IL-5Rα and antibodies that bind to CD3α;

[0111] scFv antibodies that bind to IL-5Rα and scFv antibodies that bind to CD3α;

[0112] An antibody comprising a Fab that binds to IL-5Rα and a Fab that binds to CD3α; and

[0113] BiTE (Bi-specific T-cell engager) binding to IL-5Rα and CD3α and scFv antibody binding to CD3α.

[0114] The above bispecific antibodies refer to antibodies obtained from a substantially homogeneous antibody population, i.e., antibodies that are identical except for possible naturally occurring mutations that may be present in trace amounts in the individual antibodies comprising the population. Bispecific antibodies are highly specific, being directed against a single antigenic site on each of two antigens.

[0115] For example, the bispecific antibodies useful in the present invention can be prepared by the quadrosome method, or can be prepared using recombinant DNA methods in bacterial, eukaryotic or plant cells.

[0116] The term "affinity" refers to the ability of an antibody to specifically recognize and bind to a specific site of an antigen. High affinity, along with the specificity of an antibody for an antigen, is an important factor in the immune response. The affinity constant (K) D ) can be determined using surface plasmon resonance (SPR), e.g., BIAcore, bio-layer interferometry. Surface plasmon resonance data can be used to fit a 1:1 Langmuir binding model (simultaneously k on , k off ) and rate constant k off / k on Affinity constant (K) calculated from the ratio of D ) is obtained.

[0117] The binding affinity of anti-IL-5Rα antibody 5R65.7 to IL-5Rα is 10 -5 M to 10 -12 is within the M range. For example, the binding affinity is 10 -6 M to 10 -12 M, 10 -7 M to 10 -12 M, 10 -8 M to 10 -12 M, 10 -9 M to 10 -12 M, 10 -5 M to 10 -11 M, 10 -6 M to 10 -11 M, 10 -7 M to 10 -11 M, 10 -8 M to 10 -11 M, 10 -9 M to 10 -11 M, 10 -10 M to 10 -11 M, 10 -5 M to 10-10 M, 10 -6 M to 10 -10 M, 10 -7 M to 10 -10 M, 10 -8 M to 10 -10 M, 10 -9 M to 10 -10 M, 10 -5 M to 10 -9 M, 10 -6 M to 10 -9 M, 10 -7 M to 10 -9 M, 10 -8 M to 10 -9 M, 10 -5 M to 10 -8 M, 10 -6 M to 10 -8 M, 10 -7 M to 10 -8 M, 10 -5 M to 10 -7 M, 10 -6 M to 10 -7 M or 10 -5 M to 10 -6 It's M.

[0118] The binding affinity of anti-CD3ε antibody SP34 to CD3ε is 10 -5 M to 10 -12 is within the M range. For example, the binding affinity is 10 -6 M to 10 -12 M, 10 -7 M to 10 -12 M, 10 -8 M to 10 -12 M, 10 -9 M to 10 -12 M, 10 -5 M to 10 -11 M, 10 -6 M to 10 -11 M, 10 -7 M to 10 -11 M, 10 -8 M to 10 -11 M, 10 -9 M to 10-11 M, 10 -10 M to 10 -11 M, 10 -5 M to 10 -10 M, 10 -6 M to 10 -10 M, 10 -7 M to 10 -10 M, 10 -8 M to 10 -10 M, 10 -9 M to 10 -10 M, 10 -5 M to 10 -9 M, 10 -6 M to 10 -9 M, 10 -7 M to 10 -9 M, 10 -8 M to 10 -9 M, 10 -5 M to 10 -8 M, 10 -6 M to 10 -8 M, 10 -7 M to 10 -8 M, 10 -5 M to 10 -7 M, 10 -6 M to 10 -7 M or 10 -5 M to 10 -6 It's M.

[0119] The above "humanized" forms of non-human (e.g., mouse) antibodies are chimeric antibodies that contain minimal sequence derived from a non-human immunoglobulin. In most cases, humanized antibodies are human immunoglobulins (recipient antibody) in which residues from the hypervariable region of the recipient antibody have been replaced with residues from the hypervariable region of a non-human species (donor antibody) that retains the desired specificity, affinity, and ability, such as mouse, rat, rabbit, or non-human primate.

[0120] The above "human antibody" means a molecule derived from human immunoglobulin, and the entire amino acid sequence constituting the antibody, including the complementarity determining region and structural region, is composed of human immunoglobulin.

[0121] "Chimeric" antibodies (immunoglobulins) in which a portion of the heavy and / or light chain is identical with or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical with or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies that exhibit the desired biological activity.

[0122] The "variable region" of the bispecific antibody used in the present invention refers to the light chain and heavy chain portions of the antibody molecule, which include the amino acid sequences of the complementarity determining regions (CDRs; i.e., CDR1, CDR2, and CDR3) and the framework regions (FR). VH refers to the variable domain of the heavy chain. VL refers to the variable domain of the light chain.

[0123] "Complementary determining region (CDR)" refers to the amino acid residues in an antibody variable domain that are necessary for antigen binding. Each variable domain typically has three CDR regions, identified as CDR1, CDR2, and CDR3.

[0124] An antibody (immunoglobulin) heavy chain constant region (Fc) pair comprising a first Fc region and a second Fc region, wherein the Fc pair may be a heterodimer comprising a mutation in the CH3 domain of the first Fc region or the second Fc region.

[0125] The antibody may bind to the C-terminus or N-terminus of the first Fc region or the second Fc region, but is not limited thereto.

[0126] The CH3 domain mutation of the first Fc region or the second Fc region may comprise one or more mutations selected from the following group, and the mutation position may be according to the EU index:

[0127] (1) Substitution of K360 position in the CH3 domain of the first Fc region with K360E;

[0128] (2) Substitution of K409W at position K409 in the CH3 domain of the first Fc region;

[0129] (3) Substitution of E347R at position E347 in the CH3 domain of the second Fc region; and

[0130] (4) Substitution of F405 position to F405T and substitution of D399 position to D399V in the CH3 domain of the second Fc region.

[0131] Specifically, the bispecific antibody according to the present invention may include the amino acid sequences described in Table 1 and Table 5. Specifically, it may include the sequences of SEQ ID NOs: 33 to 51.

[0132] From another perspective, the present invention relates to a nucleic acid encoding the bispecific antibody. The nucleic acid encoding the bispecific antibody of the present invention can be isolated to recombinantly produce multiple bispecific antibodies.

[0133] The term "amino acid" or "amino acid residue" as used herein typically refers to an amino acid having its art-recognized definition, such as an amino acid selected from alanine (Ala or A); arginine (Arg or R); asparagine (Asn or N); aspartic acid (Asp or D); cysteine ​​(Cys or C); glutamine (GIn or Q); glutamic acid (GIu or E); glycine (GIy or G); histidine (His or H); isoleucine (He or I); leucine (Leu or L); lysine (Lys or K); methionine (Met or M); phenylalanine (Phe or F); proline (Pro or P); serine (Ser or S); threonine (Thr or T); tryptophan (Trp or W); tyrosine (Tyr or Y); and valine (VaI or V). In general, amino acids can be grouped into those having nonpolar side chains (e.g., Ala, Cys, He, Leu, Met, Phe, Pro, VaI); negatively charged side chains (e.g., Asp, GIu); positively charged side chains (e.g., Arg, His, Lys); or uncharged polar side chains (e.g., Asn, Cys, GIn, GIy, His, Met, Phe, Ser, Thr, Trp, and Tyr).

[0134] The term “fluorescent label” as used herein means any molecule that can be detected through its intrinsic fluorescent properties. Suitable fluorescent labels include fluorescein, rhodamine, tetramethylrhodamine, eosin, erythrosine, coumarin, methyl-coumarin, pyrene, malacite green, stilbene, Lucifer Yellow, Cascade Blue J, Texas Red, IAEDANS, EDANS, BODIPY FL, LC Red 640, Cy 5, Cy 5.5, LC Red 705, Oregon Green, Alexa-Fluor dyes (Alexa Fluor 350, Alexa Fluor 430, Alexa Fluor 488, Alexa Fluor 546, Alexa Fluor 568, Alexa Fluor 594, Alexa Fluor 633, Alexa Fluor 660, Alexa Fluor 680), Cascade Blue, Cascade Yellow, and Examples of suitable optical dyes that include fluorophores include, but are not limited to, R-phycoerythrin (PE) (Molecular Probes, Eugene, OR), FITC, rhodamine, and Texas Red (Pierce, Rockford, IL), Cy5, Cy5.5, Cy7 (Amersham Life Science, Pittsburgh, PA). Suitable optical dyes containing fluorophores are described in the Molecular Probes Handbook by Richard P. Haugland.

[0135] "Nucleic acid" is a comprehensive term encompassing DNA (gDNA and cDNA) and RNA molecules. Nucleotides, the basic structural units of nucleic acids, include not only natural nucleotides but also analogues with modified sugar or base moieties. The sequence of the nucleic acid encoding the heavy and light chain variable regions of the present invention may be modified. Such modifications include additions, deletions, non-conservative substitutions, or conservative substitutions of nucleotides.

[0136] The DNA encoding the antibody can be readily isolated or synthesized using conventional molecular biological techniques (e.g., by using an oligonucleotide probe that can specifically bind to the DNA encoding the antibody and its heavy and light chains), and the nucleic acid can be isolated and inserted into a replicable vector for further cloning (DNA amplification) or further expression. Based on this, the present invention relates to a recombinant expression vector comprising the nucleic acid from another aspect.

[0137] As used herein, the term "vector" refers to a means for expressing a target gene in a host cell, and includes viral vectors such as plasmid vectors, cosmid vectors, bacteriophage vectors, adenovirus vectors, retrovirus vectors, and adeno-associated virus vectors. Components of a vector typically include, but are not limited to, one or more of the following: a signal sequence, an origin of replication, one or more antibiotic resistance marker genes, an enhancer element, a promoter, and a transcription termination sequence. A nucleic acid encoding an antibody is operably linked to the promoter and the transcription termination sequence, etc.

[0138] "Operably linked" means a functional association between a nucleic acid expression regulatory sequence (e.g., a promoter, a signal sequence, or an array of transcription factor binding sites) and another nucleic acid sequence, whereby the regulatory sequence regulates transcription and / or translation of the other nucleic acid sequence.

[0139] In the case of a prokaryotic cell as a host, it is common to include a strong promoter that can drive transcription (e.g., tac promoter, lac promoter, lacUV5 promoter, lpp promoter, pLλ promoter, pRλ promoter, rac5 promoter, amp promoter, recA promoter, SP6 promoter, trp promoter, and T7 promoter), a ribosome binding site for translation initiation, and a transcription / translation termination sequence. In addition, for example, when a eukaryotic cell is used as a host, promoters derived from the genome of mammalian cells (e.g., metallothionine promoter, β-actin promoter, human hemoglobin promoter, and human muscle creatine promoter) or promoters derived from mammalian viruses (e.g., adenovirus late promoter, vaccinia virus 7.5K promoter, SV40 promoter, cytomegalovirus (CMV) promoter, tk promoter of HSV, mouse mammary tumor virus (MMTV) promoter, LTR promoter of HIV, Moloney virus promoter, Epstein-Barr virus (EBV) promoter, and Rous sarcoma virus (RSV) promoter) can be used, and generally have a polyadenylation sequence as a transcription termination sequence.

[0140] In some cases, the vector may be fused with other sequences to facilitate purification of the antibody expressed therefrom. Such fusion sequences include, for example, glutathione S-transferase (Pharmacia, USA), maltose binding protein (NEB, USA), FLAG (IBI, USA), and 6x His (hexahistidine; Qiagen, USA).

[0141] The above vector contains antibiotic resistance genes commonly used in the art as selectable markers, for example, resistance genes for ampicillin, gentamicin, carbenicillin, chloramphenicol, streptomycin, kanamycin, geneticin, neomycin and tetracycline.

[0142] In another aspect, the present invention relates to a host cell transfected with the recombinant expression vector. The host cell used to produce the antibody of the present invention may be a prokaryotic cell, yeast cell, or higher eukaryotic cell, but is not limited thereto.

[0143] Prokaryotic host cells can be used, such as strains of the genus Bacillus, such as Escherichia coli, Bacillus subtilis and Bacillus thuringiensis, Streptomyces, Pseudomonas (e.g., Pseudomonas putida), Proteus mirabilis and Staphylococcus (e.g., Staphylococcus carnosus).

[0144] However, animal cells are of greatest interest, and examples of useful host cell lines include, but are not limited to, COS-7, BHK, CHO, CHOK1, DXB-11, DG-44, CHO / -DHFR, CV1, COS-7, HEK293, BHK, TM4, VERO, HELA, MDCK, BRL 3A, W138, Hep G2, SK-Hep, MMT, TRI, MRC 5, FS4, 3T3, RIN, A549, PC12, K562, PER.C6, SP2 / 0, NS-0, U20S, or HT1080.

[0145]

[0146] In another aspect, the present invention relates to a method for producing a bispecific antibody, comprising: a step of culturing the host cell to produce a bispecific antibody; and a step of isolating and purifying the produced bispecific antibody.

[0147]

[0148] Specifically, the method for producing a bispecific antibody binding to human IL-5Rα and CD3ε according to the present invention is

[0149] (a) a step of culturing a host cell expressing an antibody that binds to human IL-5Rα according to the present invention and an antibody that binds to human CD3ε to produce an antibody that binds to human IL-5Rα and human CD3ε according to the present invention; and

[0150] (b) a step of recovering the produced bispecific antibody;

[0151] May be characterized by including, but not limited to.

[0152]

[0153] The host cells described above can be cultured in various media. Any commercially available medium can be used as a culture medium. Any other essential supplements known to those skilled in the art may be included at appropriate concentrations. Culture conditions, such as temperature and pH, are already used with the host cells selected for expression and will be readily apparent to those skilled in the art.

[0154] The above bispecific antibody can be recovered by removing impurities, for example, by centrifugation or ultrafiltration, and the resultant product can be purified, for example, using affinity chromatography. Additional purification techniques, such as anion or cation exchange chromatography, hydrophobic interaction chromatography, and hydroxylapatite chromatography, can be used.

[0155] In another aspect, the present invention relates to a conjugate comprising the above-described bispecific antibody and a bioactive molecule selected from the group consisting of peptides, proteins, small molecule drugs, nucleic acids, nanoparticles and liposomes.

[0156] The protein may be a bispecific antibody, an antibody fragment, an immunoglobulin, a peptide, an enzyme, a growth factor, a cytokine, a transcription factor, a toxin, an antigenic peptide, a hormone, a transport protein, a motor protein, a receptor, a signaling protein, a storage protein, a membrane protein, a transmembrane protein, an internal protein, an external protein, a secreted protein, a viral protein, a glycoprotein, a truncated protein, a protein complex, or a chemically modified protein.

[0157] The term "small molecule drug" is broadly used herein to refer to an organic, inorganic, or organometallic compound having a molecular weight of less than about 1000 daltons and having activity as a therapeutic agent for diseases. The term "small molecule drug" herein includes oligopeptides and other biomolecules having a molecular weight of less than about 1000 daltons.

[0158] The above nanoparticle refers to a particle composed of materials having a diameter of 1 to 1000 nm, and the nanoparticle may be a metal / metal core-shell composite composed of a metal nanoparticle, a metal nanoparticle core, and a metal shell surrounding the core, a metal / non-metal core-shell composed of a metal nanoparticle core and a non-metal shell surrounding the core, or a non-metal / metal core-shell composite composed of a non-metal nanoparticle core and a metal shell surrounding the core. According to one specific example, the metal may be selected from, but is not limited to, gold, silver, copper, aluminum, nickel, palladium, platinum, ferromagnetic iron, and oxides thereof, and the non-metal may be selected from, but is not limited to, silica, polystyrene, latex, and acrylate series materials.

[0159] The liposomes are composed of one or more lipid bilayer membranes surrounding an aqueous internal compartment capable of self-assembly. Liposomes can be characterized by their membrane type and size. Small unilamellar vesicles (SUVs) have a single membrane and can have a diameter of 20 nm to 50 nm. Large unilamellar vesicles (LUVs) can have a diameter greater than 50 nm. Oligolamellar and multilamellar large vesicles have multiple, usually concentric, membrane layers and can have a diameter greater than 100 nm. Liposomes with multiple non-concentric membranes, i.e., multiple smaller vesicles contained within a larger vesicle, are called multivesicular vesicles.

[0160] As used herein, “fusion” refers to the integration of two molecules with different or identical functions or structures, and may be achieved by any physical, chemical, or biological method that allows the tumor-penetrating peptide to bind to the protein, small molecule drug, nanoparticle, or liposome. The fusion may preferably be achieved by a linker peptide, which may mediate the fusion with the bioactive molecule at various locations in the antibody light chain variable region, antibody, or fragment thereof of the present invention.

[0161] "T cell-mediated cytotoxicity" refers to the reaction in which T cells lyse target cells tagged with a specific bispecific antibody. Antibody-dependent cytotoxicity (ADCC) also lyses targets, but is independent of T cells, as other effector cells are involved and the immune complement system does not require other cells. ADCC typically requires effector cells known as natural killer (NK) cells that interact with immunoglobulin G (IgG) antibodies. However, macrophages, neutrophils, and eosinophils can also mediate ADCC, including eosinophils that kill certain parasitic worms known as helminths via IgE antibodies.

[0162] Bioactive molecules that can be conjugated to the antibodies according to the present invention include small molecule drugs, in particular, allergic diseases, inflammatory diseases and / or diseases caused by an increase in eosinophils, for example, hypereosinophilic syndrome (HES); hypereosinophilia; asthma such as eosinophilic asthma, eosinophilic bronchial asthma (ABA) and severe eosinophilic bronchial asthma (ABA); chronic obstructive pulmonary disease (COPD); Cherge-Strauss syndrome; eosinophilic esophagitis; eosinophilic gastroenteritis; eosinophilic gastroenteritis (EGID); Atopic diseases such as atopic dermatitis; allergic diseases such as allergic rhinitis; immunoglobulin E (IgE)-mediated food allergies; inflammatory bowel disease, allergic colitis; gastroesophageal reflux disease; endomyocardial fibrosis; Loeffler endocarditis; Davis disease; intermittent angioedema associated with eosinophilia; pseudoeosinophilia-myalgia syndrome / Spanish toxic oil syndrome; liver cirrhosis; impetigo dermatitis; bullous pemphigoid; Churg-Strauss syndrome; acute myelogenous eosinophilic leukemia; acute lymphocytic eosinophilic leukemia; systemic mast cell disease with eosinophilia; eczema; Wegner's sarcoidosis; polyarteritis nodosa; eosinophilic vasculitis; And drugs that have a therapeutic effect on rheumatoid arthritis, etc. are preferable.

[0163] More preferably, examples thereof include, but are not limited to, beta agonists such as indacaterol, formoterol, vilanterol, albuterol, levalbuterol, and theophylline; anticholinergic agents such as ipratropium, tiotropium, and glycopyrrolate; and leukotriene modifiers such as montelukast, zafirlukast, and zileuton.

[0164]

[0165] In another aspect, the present invention provides a multispecific antibody comprising the above bispecific antibody.

[0166] "Binding valency" refers to the presence of a specified number of antigen-specific binding sites within a molecule. Therefore, the terms "monovalent" and "bivalent" refer to the presence of one and two antigen-specific binding sites, respectively, within a molecule.

[0167] A multispecific antibody is an antibody that has binding specificities for at least three different antigens. A multispecific antibody may include an antibody that targets more than three targets, such as a trispecific antibody, a tetraspecific antibody, or an antibody that targets more than one target.

[0168]

[0169] The antibody capable of forming a multi-specific antibody using the antibody according to the present invention can be used in combination with the IL-5Rα×CD3ε T cell engaging bispecific antibody according to the present invention to treat diseases caused by an increase in eosinophils, such as hypereosinophilic syndrome (HES); hypereosinophilia; asthma such as eosinophilic asthma, eosinophilic bronchial asthma (ABA), and severe eosinophilic bronchial asthma (ABA); chronic obstructive pulmonary disease (COPD); Cherge-Strauss syndrome; eosinophilic esophagitis; eosinophilic gastroenteritis; eosinophilic gastroenteritis (EGID); Atopic diseases such as atopic dermatitis; allergic diseases such as allergic rhinitis; immunoglobulin E (IgE)-mediated food allergies; inflammatory bowel disease, allergic colitis; gastroesophageal reflux disease; endomyocardial fibrosis; Loeffler endocarditis; Davis disease; intermittent angioedema associated with eosinophilia; pseudoeosinophilia-myalgia syndrome / Spanish toxic oil syndrome; liver cirrhosis; impetigo dermatitis; bullous pemphigoid; Churg-Strauss syndrome; acute myelogenous eosinophilic leukemia; acute lymphocytic eosinophilic leukemia; systemic mast cell disease with eosinophilia; eczema; Wegner's sarcoidosis; polyarteritis nodosa; eosinophilic vasculitis; If it is an antibody that can have a synergistic or additive therapeutic effect in the prevention or treatment of rheumatoid arthritis, etc., it can be used without restriction.

[0170] Preferred examples include, but are not limited to, anti-IgE antibodies such as omalizumab and ligelizumab, and antibodies to anti-interleukin or anti-interleukin receptors, such as anti-IL4R antibodies.

[0171] In another aspect, the present invention relates to a composition for removing eosinophils, comprising the above-described bispecific antibody or an antigen-binding fragment thereof as an active ingredient.

[0172] The conventional method of suppressing eosinophils was to remove eosinophils by inducing ADCC through natural killer cells with an antibody against IL5Ra, but according to the present invention, in order to remove eosinophils, which are the main cause of asthma and allergies, T cells can induce eosinophil cell lysis through a bispecific antibody targeting an antigen specifically expressed on eosinophils.

[0173] From another aspect, the present invention relates to a composition for the prevention or treatment of allergic diseases, inflammatory diseases, and / or diseases caused by an increase in eosinophils, particularly diseases caused by eosinophilia, comprising the above-described bispecific antibody or an antigen-binding fragment thereof as an active ingredient.

[0174] Examples of diseases treatable using the bispecific antibody according to the present invention include hypereosinophilic syndrome (HES); hypereosinophilia; asthma such as eosinophilic asthma, eosinophilic bronchial asthma (ABA), and severe eosinophilic bronchial asthma (ABA); chronic obstructive pulmonary disease (COPD); Cherge-Strauss syndrome; eosinophilic esophagitis; eosinophilic gastroenteritis; eosinophilic gastrointestinal disease (EGID); atopic diseases such as atopic dermatitis; allergic diseases such as allergic rhinitis; Examples include, but are not limited to, immunoglobulin E (IgE)-mediated food allergies; inflammatory bowel disease, allergic colitis; gastroesophageal reflux disease; endomyocardial fibrosis; Loeffler endocarditis; Davis disease; intermittent angioedema associated with eosinophilia; pseudoeosinophilia-myalgia syndrome / Spanish toxic oil syndrome; cirrhosis; impetigo dermatitis; bullous pemphigoid; Churg-Strauss syndrome; acute myelogenous eosinophilic leukemia; acute lymphocytic eosinophilic leukemia; systemic mast cell disease with eosinophilia; eczema; Wegner's sarcoidosis; polyarteritis nodosa; eosinophilic vasculitis; and rheumatoid arthritis.

[0175]

[0176] The present invention relates to a pharmaceutical composition for the prevention or treatment of allergic diseases, inflammatory diseases and / or diseases caused by an increase in eosinophils, comprising (a) a pharmaceutically effective amount of a bispecific antibody according to the present invention; and (b) a pharmaceutically acceptable carrier.

[0177] The present invention also relates to a method for preventing or treating allergic diseases, inflammatory diseases and / or diseases caused by an increase in eosinophils, comprising a step of administering a bispecific antibody according to the present invention in an effective amount required for a patient.

[0178] The bispecific antibody according to the present invention is useful for the prevention or treatment of IL-5-mediated diseases by eliminating, inhibiting, or reducing IL-5 activity. The bispecific antibody according to the present invention binds to IL-5Rα and is used for the treatment of diseases associated with IL-5 activity. Examples include, but are not limited to, eosinophilic asthma, chronic obstructive pulmonary disease (COPD), Cherge-Strauss syndrome, eosinophilic esophagitis, eosinophilic gastroenteritis, and heavy chain cell syndrome.

[0179] To treat the above autoimmune disease or related autoimmune condition, the IL-5Rα×CD3ε T cell engaging bispecific antibody of the present invention may be administered to a patient in combination with other therapeutic agents using multidrug therapy. The IL-5Rα×CD3ε T cell engaging bispecific antibody may be administered concurrently with, sequentially or alternating with, an immunosuppressant, or after resistance to other therapies has developed. The immunosuppressant may be administered at the same or lower dose as used in the art. The choice of preferred immunosuppressant may depend on many factors, including the type of disease to be treated and the patient's medical history.

[0180]

[0181] "Prevention" means any action of inhibiting or delaying the progression of an allergic disease, an inflammatory disease, and / or a disease caused by an increase in eosinophils by administering a composition according to the present invention, and "treatment" means inhibiting the development of an allergic disease, an inflammatory disease, and / or a disease caused by an increase in allergic disease, an inflammatory disease, and / or an eosinophils, alleviating an allergic disease, an inflammatory disease, and / or a disease caused by an increase in eosinophils, etc. The antibody of the present invention can be usefully utilized both in vitro and in vivo in applications related to IL-5Rα expressing cells.

[0182] The pharmaceutical composition of the present invention may contain the bispecific or the conjugate according to the present invention, and may additionally include a pharmaceutically acceptable carrier for administration of the pharmaceutical composition of the present invention to the above components. The term "pharmaceutically acceptable carrier" as used herein refers to a carrier or diluent that does not stimulate a living organism and does not inhibit the biological activity and properties of the administered compound. In a composition formulated as a liquid solution, the pharmaceutically acceptable carrier may be a sterile and biocompatible one, such as saline solution, sterile water, buffered saline solution, albumin injection solution, dextrose solution, maltodextrin solution, glycerol, and a mixture of one or more of these components. If necessary, other conventional additives such as antioxidants, buffers, and bacteriostatic agents may be added. In addition, diluents, dispersants, surfactants, binders, and lubricants may be additionally added to formulate the composition into an injectable formulation such as an aqueous solution, suspension, or emulsion, or into a pill, capsule, granule, or tablet.

[0183] The pharmaceutical composition of the present invention may be in various oral or parenteral dosage forms. When formulated, it is prepared using diluents or excipients such as commonly used fillers, bulking agents, binders, wetting agents, disintegrating agents, and surfactants. Solid preparations for oral administration include tablets, pills, powders, granules, and capsules, and these solid preparations are prepared by mixing one or more compounds with at least one excipient, such as starch, calcium carbonate, sucrose or lactose, gelatin, etc. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Liquid preparations for oral administration include suspensions, oral solutions, emulsions, and syrups, and in addition to commonly used simple diluents such as water and liquid paraffin, various excipients such as wetting agents, sweeteners, fragrances, and preservatives may be included. Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, lyophilized preparations, and suppositories. Non-aqueous solutions and suspensions can include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate. Suppository bases include witepsol, macrogol, Tween 61, cocoa butter, laurin, and glycerogelatin.

[0184] The method of treatment using the bispecific antibody or conjugate of the present invention comprises administering a pharmaceutically effective amount of the bispecific antibody or conjugate. It will be apparent to those skilled in the art that an appropriate total daily dosage can be determined by a treating physician within the scope of sound medical judgment. In addition, the dosage may be administered once or in several divided doses. However, for the purposes of the present invention, the specific therapeutically effective amount for a specific patient is preferably applied differently depending on various factors including the type and degree of response to be achieved, the specific composition including whether other agents are used in some cases, the patient's age, weight, general health, sex, and diet, the time of administration, route of administration, and treatment period, drugs used together or concurrently with the specific composition, and similar factors well known in the medical field.

[0185] The subject to which the composition of the present invention is administered includes, without limitation, mammals including humans.

[0186] The term "administration" of the present invention means introducing the pharmaceutical composition of the present invention to a patient by any appropriate method, and the route of administration of the composition of the present invention may be administered through various routes, whether or not it can reach the target tissue.

[0187] The dual specificity according to the present invention can be used as a single drug or in combination with existing therapeutic agents.

[0188] Drugs that can be used for combination therapy with the bispecific antibody according to the present invention include diseases caused by an increase in eosinophils, such as hypereosinophilic syndrome (HES); hypereosinophilia; asthma such as eosinophilic asthma, eosinophilic bronchial asthma (ABA), and severe eosinophilic bronchial asthma (ABA); chronic obstructive pulmonary disease (COPD); Cherge-Strauss syndrome; eosinophilic esophagitis; eosinophilic gastroenteritis; eosinophilic gastroenteritis (EGID); atopic diseases such as atopic dermatitis; Allergic diseases such as allergic rhinitis; immunoglobulin E (IgE)-mediated food allergy; inflammatory bowel disease, allergic colitis; gastroesophageal reflux disease; endomyocardial fibrosis; Loeffler endocarditis; Davis disease; intermittent angioedema associated with eosinophilia; pseudoeosinophilia-myalgia syndrome / Spanish toxic oil syndrome; liver cirrhosis; impetigo; bullous pemphigoid; Churg-Strauss syndrome; acute myelogenous eosinophilic leukemia; acute lymphocytic eosinophilic leukemia; systemic mast cell disease with eosinophilia; eczema; Wegner's sarcoidosis; polyarteritis nodosa; eosinophilic vasculitis; and rheumatoid arthritis may be used without restriction.

[0189] Preferably, beta agonists such as indacaterol, formoterol, vilanterol, albuterol, levalbuterol, and theophylline; anticholinergic agents such as ipratropium, tiotropium, and glycopyrrolate; leukotriene modifiers such as montelukast, zafirlukast, and zileuton; Examples include, but are not limited to, inhaled corticosteroids such as fluticasone propionate, budesonide, ciclesonide, beclomethasone, mometasone, and fluticasone furoate; and anti-IgE antibodies such as omalizumab and ligelizumab.

[0190]

[0191] The present invention also relates to a method for treating a disease comprising administering a bispecific antibody according to the present invention to a patient in need of treatment.

[0192]

[0193] From another perspective, the present invention provides a diagnostic composition for allergic diseases, inflammatory diseases, and / or diseases caused by an increase in eosinophils, comprising the above-described bispecific antibody or an antigen-binding fragment thereof. Furthermore, the present invention provides a diagnostic kit for allergic diseases, inflammatory diseases, and / or diseases caused by an increase in eosinophils, comprising the above-described diagnostic composition.

[0194] As used herein, "diagnosis" refers to confirming the presence or characteristics of a pathophysiological condition. Diagnosis in the present invention refers to confirming the onset and progression of an allergic disease, an inflammatory disease, and / or a disease caused by an increase in eosinophils.

[0195] For diagnostic methods using a bispecific antibody according to the present invention, the drug may include a detectable label used to detect the presence of IL-5Rα antigen-expressing cells in vitro or in vivo. Radioisotopes that can be detected in vivo, such as labels detectable using scintigraphy, magnetic resonance imaging, or ultrasound, can be used for clinical diagnostic applications. Useful scintigraphy labels include positron emitters and γ-emitters. Representative contrast agents for magnetic source imaging include paramagnetic or superparamagnetic ions (e.g., iron, copper, manganese, chromium, erbium, europium, dysprosium, holmium, and gadolinium), iron oxide particles, and water-soluble contrast agents. For ultrasound detection, gases or liquids can be entrapped within porous inorganic particles that release microbubble contrast agents. Detectable labels useful for in vitro detection include fluorophores, detectable epitopes or binders, and radioactive labels.

[0196] The diagnostic kit for the above allergic disease, inflammatory disease and / or disease caused by an increase in eosinophils may further comprise a composition, solution or device having one or more kinds of other components suitable for the analysis method.

[0197] In one embodiment, the kit may include a bottle, vial, bag, syringe, or syringe. The container may be formed from a variety of materials, such as glass, plastic, or metal. A label included with the container may indicate directions for use. Additionally, other materials desirable from a commercial and user perspective, such as other buffers, diluents, filters, needles, syringes, etc., may be included.

[0198]

[0199] The present invention will be described in more detail below through examples. The present invention will be described in more detail below through examples. However, these examples are intended to exemplify the present invention and are not intended to limit the scope of the present invention.

[0200]

[0201] Example 1: Construction of IL-5Rα×CD3ε T cell-engaging bispecific antibodies in eight formats.

[0202] The structure of the target cell and the target antigen expressed on the target cell and the epitope targeted by the T cell-mediated bispecific antibody are different, and the affinity including the avidity effect due to the difference in binding valency for each antigen is different for each format of the bispecific antibody, and the degree of T cell-mediated cytotoxicity is different depending on how closely the cytolytic synapse is formed between the T cell and the eosinophil due to the difference in the size (molecular weight) of the T cell-engaged bispecific antibody. Therefore, in order to select the T cell-engaged bispecific antibody format that can most efficiently eliminate the target cell, eight formats (Diabody-Fc, scFv(L) / scFv-Fc, scFV(H) / scFv-Fc, BiTE-Fc, scFv / Fab-Fc, IgG analogue, BiTE(L) / scFv-Fc, BiTE(H) / scFv-Fc, T cell-engaging bispecific antibodies capable of specifically and simultaneously binding to human interleukin-5 receptor α and (IL-5Rα) and CD3ε (Fig. 1) were constructed. The Fc variants for construction of the fusion protein were based on IgG1, and the EW-RVT mutations were introduced to form a heterodimeric heavy chain constant region (Heterodimeric Fc) and the L234F / L235E / D265A mutations (hereinafter referred to as FEA mutations) were introduced to prevent unnecessary in vivo clearance due to unintended ADCC / ADCP / CDC functions, thereby forming a heterodimer. A heterodimeric heavy chain constant region Fc (γ1, FEA, EW-RVT) was used (Liu et al, 2020). The names, drawings, predicted molecular weights, and expression levels of eight bispecific antibody formats are shown in Figure 1 (Figure 1).

[0203] Figures 2a-2h illustrate schematic diagrams of nucleic acids for expressing each format of IL-5Rα×CD3ε T cell-engaging bispecific antibodies. DNA encoding proteins into which heterodimeric heavy-chain constant region Fc mutant pairs were introduced was cloned in-frame into pcDNA3.4(+) (Invitrogen, USA), an animal cell expression vector with a CMV promoter, using NotI / HindIII, with a signal sequence, a nucleic acid sequence encoding SEQ ID NO: 27-42, and a stop codon. The VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 sequences of 5R65.7 and SP34 used here are as follows:

[0204]

[0205] Additionally, for negative controls in subsequent biological activity experiments, HER2×CD3ε IgG analogs were constructed by replacing the CDR regions within the VH and VL of the anti-IL-5Rα antibody 5R65.7 with Trastuzumab, which targets HER2. Figure 2i shows a schematic diagram of four nucleic acids for expressing HER2×CD3ε IgG analogs (Figure i).

[0206] Table 1 below shows the amino acid sequences encoded by the nucleic acid sequences used in the construction of the IL-5Rα×CD3ε T cell engaging bispecific antibodies of the above eight formats and the control bispecific antibodies included in the examples described later.

[0207]

[0208]

[0209]

[0210]

[0211]

[0212]

[0213] Example 2: Expression / purification of IL-5Rα×CD3ε T cell-engaging bispecific antibodies in eight formats

[0214] For the expression and purification of IL-5Rα×CD3ε T cell-engaging bispecific antibodies in eight formats, HEK293F (Invitrogen) cells were transiently transfected. 1.0×10 HEK293F cells were transfected in 100 mL of a shaker flask. 6The cells were seeded in 90 ml of medium at a density of 10 cells / ml and incubated at 120 rpm, 8% CO2, and 37°C. For Diabody-Fc, scFv(L) / scFv-Fc, scFv(H) / scFv-Fc, BiTE-Fc, BiTE(L) / scFv-Fc, BiTE(H) / scFv-Fc, CH3A (EW) 62.5 μg, CH3B(RVT) 62.5 μg (CH3A(EW):CH3B(RVT)=1:1), for scFv / Fab-Fc, CH3A (EW) 41.7 μg, CH3B (RVT) 41.7 μg, light chain binding to CH3B heavy chain 41.7 μg (CH3A(EW):CH3B(RVT):light chain binding to CH3B heavy chain=1:1:1), for IgG analogues, CH3A (EW) 31.25 μg, CH3B (RVT) 31.25 μg, 31.25 μg of light chain binding to CH3A heavy chain, 31.25 μg of light chain binding to CH3B heavy chain (CH3A (EW): CH3B (RVT): Light chain binding to CH3A heavy chain: Light chain binding to CH3B heavy chain = 1:1:1:1) Therefore, a total of 125 μg of the constructed plasmid was diluted and filtered in 4 ml of serum-free Freestyle 293 expression medium (Invitrogen), mixed with 6 ml of medium in which 375 μg of polyethylenimine (PEI) was diluted, and reacted at room temperature for 10 minutes. After that, the reacted mixed medium was added to the cells seeded in 90 ml previously, incubated at 135 rpm, 8% CO2, and cultured for 6 days. As a result, the produced protein is secreted outside the cells and accumulates in the medium. Therefore, the protein was purified using a protein A Sepharose column (GE healthcare) from the cell culture supernatant collected by centrifugation at 3800 rpm for 25 minutes after cell culture.At this time, the purification method referred to the standard protocol provided by the protein A column company, and the eluted protein was concentrated after exchanging the buffer with 1× PBS using a Vivaspin 30,000 MWCO (Satorius) centrifugal concentrator. The purified protein was measured for absorbance at a wavelength of 562 nm using a solution in the BCA protein assay kit (Thermo) and the amount was quantified according to the drawn standard curve. Figure 1 shows the purification yield according to each format. The result value was expressed as the standard error of the mean (mean±SD) after performing three independent experiments.

[0215]

[0216] Example 3: Purity and physical properties analysis of eight IL-5Rα×CD3ε T cell engaging bispecific antibodies.

[0217] The purity of 3 μg of the purified bispecific antibody proteins of the eight formats above was confirmed by SDS-PAGE analysis (Fig. 3a). For each format, the protein band matching the predicted molecular weight from the results of non-reducing conditions is marked with a red box. Among the purified proteins, scFv(H) / scFv-Fc, BiTE-Fc, scFv / Fab-Fc, and BiTE(H) / scFv-Fc did not show the desired antibody purity, and aggregates and unassembled bands in which the two complementary heavy chains CH3A and CH3B did not bind were observed. In addition, analysis of the results of reducing conditions (RE) of those formats confirmed that the expression levels of the complementary heavy chains CH3A and CH3B were different even though they were transfected with the same amount of nucleic acid.

[0218] Figure 3b is a chromatogram showing the mAU values ​​at 280 nm versus time (minutes) obtained by performing SEC (Size Exclusion Chromatography) for quantitative physical property analysis of IL-5Rα×CD3ε T cell-engaging bispecific antibodies in eight formats. Measurements were performed using an HPLC (Agilent Technologies, USA) instrument and a Superdex200 10 / 300 GL column (Cytiva, USA) according to the following specific protocol.

[0219] Prepare 1× PBS (pH 7.4, 12 mM phosphate, 137 mM NaCl, 2.7 mM KCl) that has been filtered and degassed. Dilute eight formats of IL-5Rα × CD3ε T cell-engaging bispecific antibodies to a concentration of 1 μg / μl and place 30 μl each into 250 μl inserts with Polymer Feet, 100 / PK (Agilent Technologies, USA) and place them in an autosampler vial to prepare the final sample to be analyzed. In addition, markers that can distinguish the size of unknown protein samples were also prepared under the same concentration conditions. The marker corresponding to 150 kDa is Alcohol dehydrogenase, and the marker corresponding to 66 kDa is BSA.

[0220] First, 2-3 times the column volume of the third solution was flowed at 0.5 ml / min to remove the initial storage buffer (20% ethanol) in the column and perform the standardization process. Once this was completed, 2-3 times the volume of 1× PBS (pH 7.4, 137 mM NaCl), a physiological condition running buffer, was flowed at 0.75 ml / min to complete the standardization process before starting the analysis. After placing the prepared sample for analysis in the device, the analysis was performed at a flow rate of 0.75 ml / min, an injection amount of 30 μg (only 30 μl of the prepared 45 μl sample was injected), 40 minutes of analysis, and a 10-minute post time. When the sample injector injects the set injection amount of the sample, it flows into the buffer-flowing tube and is injected into the column. When a buffer containing a sample passes through a column compressed with porous resin, the time it takes for the protein in the sample to elute out of the column varies depending on its molecular weight, or size. The physical properties were analyzed through a chromatogram obtained by measuring the change in absorbance at 280 nm. At this time, the smaller the protein size, the more it passes through the inside of the porous resin and elutes at a later time, and the larger the protein size, the faster it passes through the column by passing through the outside of the porous resin. This principle allows the interpretation of the chromatogram.

[0221] The purity and properties of eight formats of IL-5Rα×CD3ε T cell-engaging bispecific antibodies were analyzed using SDS-PAGE and SEC analysis (Fig. 3b). The properties of Diabody-Fc, scFv(L) / scFv-Fc, IgG analog, and BiTE(L) / scFv-Fc were found to have desirable properties due to their homogeneous protein composition. However, scFv(H) / scFv-Fc, BiTE-Fc, scFv / Fab-Fc, and BiTE(H) / scFv-Fc were not included in the in-vitro and ex-vivo experiments using cell lines transformed to express IL-5Rα, activated PBMCs, and eosinophils, which will be mentioned in Example 5 and thereafter, as they have a heterogeneous protein composition, which exists as an undesirable aggregate or an unassembled protein in which the CH3A and CH3B chains are not combined, and have undesirable properties.

[0222]

[0223] Example 4: Construction of a K562 cell line expressing IL-5Rα (K562 / IL-5Rα).

[0224] To compare the biological activity of four types of IL-5Rα×CD3ε T cell-engaging bispecific antibodies, cell lines were first established. Specifically, DNA encoding IL-5Rα was cloned into the lentivirus vector pLJM1 (Addgene) with SalI / EcoRI. 3 x 10 6HEK293T cells were cultured in 10 ml of medium containing 10% FBS for 12 hours under 5% CO2, 37°C. Once the cells were stabilized, the medium was removed, and the plates were washed with DPBS (Welgene, LB001-04). 40 μl of Lipofectamine 3000 (Invitrogen, USA) was added to 600 μl of Opti-MEM media (Gibco), and the constructed lentiviral vector and viral packaging vectors pMDL, pRSV, and pVSV-G (Addgene) were carefully added. The cells were incubated at room temperature for 20 minutes and then added to the plates. Additionally, 9 ml of antibiotic-free DMEM media was added, and the cells were cultured for 6 hours at 37°C, 5% CO2. The medium was replaced with 10 ml of DMEM medium containing 10% FBS, and the cells were cultured for 48 hours. The medium containing the transient transfection with the lentiviral vector was filtered and the viral particles were added to a cell culture dish containing K562 cells prepared in advance. The puromycin resistance gene was used as a selection marker for antibiotic resistance.

[0225]

[0226] Example 5: Isolation of human PBMCs and production of activated PBMCs

[0227] In the 'T cell-mediated cytotoxicity induction evaluation experiment' performed in the examples of this specification, T cells and PBMCs (Activated PBMCs) produced from human PBMCs were used as effector cells. First, to isolate human PBMCs from human blood, blood from a healthy donor was diluted 1:1 with DPBS, and 20 ml of Ficoll-Paque solution (GE Healthcare, 17-5442-03) was dispensed into 50 ml polypropylene centrifuge tubes, and 20 ml of heparinized patient blood was layered on each tube. This was centrifuged at 750 × g at room temperature for 20 minutes to separate the buffy coat layer for isolating PBMCs. The separated buffy coat layer was transferred to a 50 ml polypropylene centrifuge tube, filled with DPBS to 50 ml, centrifuged at 25°C, 1500 rpm for 5 min, discarded the supernatant, filled with DPBS to 50 ml again, and centrifuged at 25°C, 1500 rpm for 5 min to wash the PBMC layer. After that, 1 × 10 PBMCs were added. 7 Each cell was dispensed into a stock solution containing FBS:DMSO = 9:1 and stored in liquid nitrogen until use.

[0228] To activate human PBMCs, Dynabeads Human T-Activator CD3 / CD28 (Gibco™, Cat#:11161D) was used, following the manufacturer's suggested protocol. After completion of the procedure, 1 × 10 7 Each cell was dispensed into 1 ml of a stock solution containing FBS:DMSO = 9:1 and stored in liquid nitrogen until use.

[0229]

[0230] Example 6: Comparison of the binding capacity of IL-5Rα×CD3ε T cell engaging bispecific antibodies of four formats to receptors expressed on the surface of cell lines expressing IL-5Rα and CD3ε.

[0231] To evaluate the binding ability of IL-5Rα×CD3ε T cell-engaging bispecific antibodies of four formats (Diabody-Fc, scFv(L) / scFv-Fc, IgG analog, BiTE(L) / scFv-Fc) showing desirable properties to the target receptors (IL-5Rα, CD3ε) expressed on the cell surface, the binding ability to the antigen expressed on the cell surface was analyzed using a FACS Calibur flow cytometer (Flow Cytometry, BD bioscience). In the receptor binding ability experiment for K562 / IL-5Rα, 5R65.7, an anti-IL-5Rα monoclonal antibody developed in a previous study, was used as a positive control for the IL-5Rα×CD3ε T cell-engaging bispecific antibody, and Trastuzumab, an anti-HER2 monoclonal antibody, and SP34, a humanized anti-CD3ε monoclonal antibody, were used as negative controls, and HER2×CD3ε IgG analogs constructed in the same format as the IgG analog format were used. The cell line expressing CD3ε used human activated PBMC. At this time, the negative control for the IL-5Rα×CD3ε T cell engaging bispecific antibody was used 5R65.7, a monoclonal antibody targeting IL-5Rα. The wild-type K562 (WT K562) cell line, which does not express both IL-5Rα and CD3ε, was used as a negative control for the cell line. Specifically, 1×10 5 K562 / IL-5Rα, activated PBMC, and K562 cells seeded at 90 μl were mixed with primary antibodies at 50 nM (K562 / IL-5Rα, K562) and 5 nM (activated PBMC), respectively, and reacted at 4°C for 60 minutes. After washing with PBSM (Miltenyi biotec; 130-091-221), Alexa Flour 647 AFFINIPURE Goat Anti-human IgG, Fcγ fragment specific 2 ndAntibodies (Jacksonimmunology, 109-605-098) were mixed at a 500:1 dilution and incubated at 4°C for 30 minutes, followed by analysis using a flow cytometer, FACS Calibur (BD Bioscience). After analysis, histograms for each sample were obtained (Fig. 4). All bispecific antibody formats exhibited receptor binding affinity for target receptors (IL-5Rα, CD3ε) at a level similar to that of the positive control, and there was no significant difference in receptor binding affinity between formats. None of the formats bound to the wild-type K562 cell line, confirming that non-specific binding to the cell surface where receptors are not expressed was not observed.

[0232]

[0233] Example 7: Binding affinity analysis of four formats of IL-5Rα×CD3ε T cell engaging bispecific antibodies (Diabody-Fc, scFv(L) / scFv-Fc, IgG analogue, BiTE(L) / scFv-Fc).

[0234] To quantitatively analyze the binding affinity for IL-5Rα and CD3ε of four IL-5Rα×CD3ε T cell-engaging bispecific antibodies (Diabody-Fc, scFv(L) / scFv-Fc, IgG analog, BiTE(L) / scFv-Fc) using Octet QK e (ForteBio, USA) Measurements were made using the device according to the protocol suggested by the manufacturer.

[0235] Specifically, each bispecific antibody was prepared by diluting it to a concentration of 5 μg / ml in DPBS (WELGENE), and IL-5Rα expressed and purified according to the method described in a previous study (Kim et al., 2021) and purchased CD3ε (sinobiological, 10977-H08H) were sequentially diluted in DPBS to concentrations of 4000, 2000, 1000, 500, 250, 125, and 0 nM, and 200 μl of each was added to an opaque 96-well plate that did not allow light to pass through. The antigen affinity of the antibody was analyzed through the change in refractive index that occurs when the antigen binds to the antibody and then detaches as the AHC (anti-human IgG Fc capture) sensor chip moves in the order of DPBS, antibody dilution solution, DPBS, antigen dilution solution, and DPBS. Affinity was calculated using Octet Data Analysis software 11.0 with a 1:1 binding model. The results are shown in Fig. 5a. Fig. 5a shows Octet QK e The results of affinity analysis of four formats of IL-5Rα×CD3ε T cell-engaging bispecific antibodies for IL-5Rα and CD3ε are presented.

[0236] The following [Table 2] shows the numerical results of affinity analysis for each single antigen.

[0237]

[0238] Meanwhile, to prove that the four IL-5Rα×CD3ε T cell-engaging bispecific antibodies constructed above can simultaneously bind to IL-5Rα and CD3ε, Octet QK e (ForteBio, USA) was used according to the following protocol. IL-5Rα and CD3ε were diluted to 4000 nM in DPBS and 200 μl each was added to an opaque 96-well plate that did not allow light to pass through.

[0239] Specifically, as the AR2G (Amine Reactive Second-Generation) sensor chip was moved in the following order: nuclease-free pure water (UPW), EDC / s-NHS diluted solution, 1 μM CD3ε diluted solution, 1 M ethanolamine solution, DPBS, and T cell-engaged bispecific antibody / diluted solution, the sequential binding of T cell-engaged bispecific antibody and IL-5Rα antigen to the CD3ε antigen immobilized on the AR2G sensor was analyzed qualitatively through two changes in refractive index that occurred simultaneously for one antibody. As a negative control, a solution diluted with HER2×CD3ε-IgG analog was added to the antibody dilution solution and the same experimental conditions were performed. The experimental results showed that for the four formats of IL-5Rα×CD3ε T cell-engaging bispecific antibodies, the refractive index increased each time the sensor was moved to the well containing the T cell-engaging bispecific antibodies and IL-5Rα, indicating that both antigens could bind to the antibodies simultaneously. However, since the HER2×CD3ε-IgG analog cannot target IL-5Rα, the refractive index decreased. Therefore, this confirms that the IL-5Rα×CD3ε T cell-engaging bispecific antibody can specifically and simultaneously bind to IL-5Rε and CD3ε (Fig. 5b).

[0240]

[0241] Example 8: Evaluation of T cell-dependent cytotoxicity-inducing ability of four formats of IL-5Rα×CD3ε T cell-engaging bispecific antibodies (Diabody-Fc, scFv(L) / scFv-Fc, IgG analog, BiTE(L) / scFv-Fc) against IL-5Rα expressing cell lines and activated T cells (Activated PBMC)

[0242] Four different IL-5Rα × CD3α bispecific antibodies exhibit differences in T cell-mediated cytotoxicity due to the different receptor binding affinity due to different formats and the distance of the cytolytic synapse formed between target cells and effector cells, i.e., T cells, due to the different antibody sizes for each format. Therefore, the present inventors evaluated the ability to induce T cell-mediated cytotoxicity in the K562 / IL-5Rα cell line expressing IL-5Rα to screen for the bispecific antibody with the format that can most effectively reduce in vivo eosinophils. Experiments were also performed on wild-type K562 to confirm non-specific T cell-mediated cytotoxicity in the cell line that does not express IL-5Rα. The effector cells used were activated PBMCs, which have more T cells and are more activated than naive PBMCs. This was done to compare the effectiveness of four formats in an environment where they can induce strong and rapid cytotoxicity by binding to T cell-engaging bispecific antibodies.

[0243] Specifically, activated PBMCs and target cells (K562 / IL-5Rα, wild-type K562) were used as effector and target cells at a ratio of 5:1, respectively. 1 x 104 / well of target cells and each of four types of IL-5Rα×CD3ε T cell-engaging bispecific antibodies and a negative control HER2×CD3ε IgG analog were diluted to 10 nM, 1 nM, 100 pM, 10 pM, 100 fM, 10 fM, and 1 fM and dispensed into a U-shaped 96-well cell culture plate. In order for the bispecific antibodies and target cells to bind to facilitate the T cell response, the cells were incubated for 1 hour at 37°C in a CO2 incubator. Afterwards, 5 x 10 4Human PBMCs were dispensed per well. Two wells were cultured for each antibody, and the final volume of each well was prepared to be 150 ㎕. Cultured for 24 hours at 37℃ in a CO2 incubator, and 2 hours before harvesting the cell suspension, 15 ㎕ of 10x lysis solution (10x Lysis buffer) was added to the sample to maximize lactate dehydrogenase (LDH) extraction. After the incubation, 50 ㎕ of cell suspension was collected from each well, and 50 ㎕ of CytoTox96® Reagent (Promega) sample was added and incubated at room temperature for 30 minutes. 50 ㎕ of reaction stop solution was added, and the absorbance was measured using a microplate reader to analyze the T cell-mediated cytotoxicity induction ability. The Y and X axes represent the % maximum cytotoxicity and antibody concentration, respectively.

[0244] Cytotoxicity (%) = (AB) / (CB) × 100

[0245] A: Release value upon antibody treatment

[0246] B: Cell spontaneous release value

[0247] C: Maximum cell release value

[0248] Analysis of the experimental results showed that, first, the IL-5Rα×CD3ε T cell-engaging bispecific antibody did not induce significant cytotoxicity against cells that did not express IL-5Rα (Fig. 6b). The scFv(L) / scFv-Fc, which could keep the two cells closest together and had a binding affinity for IL-5Rα that was approximately 2.1 times higher than the Diabody-Fc format, had the lowest EC 50It was found that the highest cytotoxicity was induced by showing the value, and after that, EC50 values ​​were formed in the order of scFv(L) / scFv-Fc, which is similar in size to scFv(L) / scFv-Fc but has a shorter hinge part, Diabody-Fc, BiTE(L) / scFv-Fc which has a binding affinity of 2 to IL-5Rα, and IgG analog format which has the largest size in the form of a monoclonal antibody (Table 3), and therefore the cytotoxicity induction ability was high in the order of scFv(L) / scFv-Fc, Diabody-Fc, BiTE(L) / scFv-Fc, and IgG analog.

[0249]

[0250]

[0251] Example 9: Evaluation of the ability of IL-5Rα×CD3ε T cell-engaging bispecific antibodies (Diabody-Fc, scFv(L) / scFv-Fc, IgG analogue, BiTE(L) / scFv-Fc) to induce IFN-γ release from activated human PBMCs.

[0252] In order to determine whether the results of the T cell-mediated cytotoxicity induction evaluation prepared in Example 8 were the result of T cells in activated PBMCs and to quantitatively evaluate the T cell activation induction ability of each format, Interferon-γ present in the supernatant was quantified using ELISA (Enzyme-Linked Immunosorbent Assay) after the T cell-mediated cytotoxicity induction evaluation. This is because, due to the nature of the bispecific antibody that induces T cell-mediated cytotoxicity by inducing T cell activation, Interferon-γ release increases proportionally depending on the degree of T cell activation. In the case of the IL-5Rα×CD3ε T cell-engaging bispecific antibody, since it is the same as the previously studied bispecific antibody in that the target cell is not a cancer cell but an in vivo eosinophil, Interferon-γ present in the supernatant was quantified to evaluate the degree of T cell activity.

[0253] For ELISA for quantifying interferon-γ, IFN gamma Human Uncoated ELISA (Invitrogen, Cat#:88-7316) was used. For the experiment, supernatants were collected from each well treated with four types of bispecific antibodies in the plate incubated for 24 hours in Example 8, and diluted 20-fold were used. After sample preparation, the experiment was performed according to the manufacturer's protocol. As with the results of Example 8, as cytotoxicity increased, the amount of interferon-γ released by T cells increased proportionally, and EC 50 The values ​​also increased in the order of scFv(L) / scFv-Fc, Diabody-Fc, BiTE(L) / scFv-Fc, and IgG analogues (Fig. 7, Table 4). When the results of Examples 8 and 9 are summarized, the cytotoxicity-inducing ability and cytokine release-inducing ability between each clone were the highest in scFv(L) / scFv-Fc, and the IgG analogues were the lowest. Considering the expression amount, physical properties, T cell-mediated cytotoxicity-inducing ability, and the degree of cytokine release-inducing ability, the format that was thought to have the best eosinophil-reducing effect was scFv(L) / scFv-Fc, and subsequent ex-vivo experiments using eosinophils were conducted using the scFv(L) / scFv-Fc format and a control group.

[0254]

[0255]

[0256] Example 10: Confirmation of IL-5Rα Expression in Human Granulocytes from Healthy Donors and Severe Asthmatic Patients

[0257] Prior to evaluating the biological activity of the IL-5Rα×CD3ε-scFv(L) / scFv-Fc T cell-engaging bispecific antibody using eosinophils, we aimed to confirm the expression of IL-5Rα on eosinophils and neutrophils in the granulocyte layer in the peripheral blood of healthy donors.

[0258] Specifically, 15 ml of Ficoll-Paque solution (GE Healthcare, 17-5442-03) was dispensed into 50 ml polypropylene centrifuge tubes, and 20 ml of heparinized healthy donor blood was layered onto each tube. The tubes were centrifuged at 750 × g at room temperature for 20 minutes to separate and collect the bottom layer. To remove mixed red blood cells, 1x RBC Lysis buffer (Invitrogen, 00-4300-54), which was diluted 10-fold with 10x RBC Lysis buffer, was dispensed up to 50 ml. Afterwards, the tubes were centrifuged at 300 × g at 25°C for 10 minutes to separate and collect the layer enriched with granulocytes (eosinophils, neutrophils) from which red blood cells were removed.

[0259] The enriched granulocytes can be classified into eosinophils and neutrophils based on the expression of Siglec-8 (sialic acid-binding immunoglobulin-like lectin 8). Eosinophils express Siglec-8, while neutrophils do not. Specifically, 1×10 for each donor sample 6 The concentrated granulocytes were mixed with 5 μl of APC anti-human Siglec-8 Ab (Biolegend; 347105) and 10 μl of PE anti-human IL-5Rα Ab (BD Pharmingen; 555902) and incubated at 4°C for 30 min. After washing with PBSM (Miltenyi biotec; 130-091-221), the samples were analyzed using a flow cytometer, FACS Calibur (BD Bioscience). After analysis, dot plots were obtained for each sample.

[0260] Figures 8 and 9 show the gating strategy for distinguishing eosinophils and neutrophils based on the presence or absence of siglec-8 expression in enriched granulocytes derived from healthy donors and patients with severe asthma, and the results of confirming the expression of IL-5Rα in eosinophils and neutrophils. Figure 10 shows the results of confirming the expression of IL-5Rα in eosinophils and neutrophils. It was confirmed that the proportion of eosinophils in patients with severe asthma was significantly higher than in healthy donors.

[0261]

[0262] Example 11: Expression and physical properties of IL-5Rα(ben)×CD3ε-scFv(L) / scFv-Fc, IL-5Rα(5R65)×CD3ε-scFv(L) / scFv-Fc, and HER2×CD3ε-scFv(L) / scFv-Fc.

[0263] The present inventors constructed a scFv(L) / scFv-Fc format with Benralizumab, an existing FDA-approved anti-IL-5Rα monoclonal antibody, and attempted to compare its ability to induce eosinophilia in vivo with that of IL-5Rα×CD3ε- scFv(L) / scFv-Fc constructed with 5R65.7. The difference between Benralizumab and 5R65.7 is the epitope and affinity for the antigen. Benralizumb has the D1 domain (Membrane distal domain) far from the cell membrane as an epitope, and its affinity for IL-5Rα is 26.8 nM, while 5R65.7 has the D3 domain (Membrane proximal domain) close to the cell membrane as an epitope, and its affinity for IL-5Rα is 4.64 nM. Therefore, when scFv(L) / scFv-Fc was constructed using Benralizumab (named IL-5Rα(ben)×CD3ε-scFv(L) / scFv-Fc) and the cytotoxicity-inducing ability was compared with IL-5Rα×CD3α scFv(L) / scFv-Fc, a problem arose in that it was unclear whether the difference was due to the difference in affinity or the difference in epitope. Therefore, compared to 5R65.7, the binding affinity to the antigen was lower, so the difference in affinity with Benralizumab was smaller, and scFv(L) / scFv-Fc was also constructed using 5R65, the parent antibody of 5R65.7 with a different epitope (named IL-5Rα(5R65)×CD3ε-scFv(L) / scFv-Fc) in an attempt to precisely identify the cause of the T cell-dependent cytotoxicity-inducing ability.

[0264] Figures 11a-11c are schematic diagrams of nucleic acids for expressing each format of IL-5Rα(ben)×CD3ε-scFv(L) / scFv-Fc, IL-5Rα(5R65)×CD3ε-scFv(L) / scFv-Fc, and HER2×CD3ε-scFv(L) / scFv-Fc T cell-engaging bispecific antibodies. DNAs encoding proteins into which heterodimeric heavy chain constant region Fc mutant pairs were introduced were cloned in-frame into pcDNA3.4(+) (Invitrogen, USA), an animal cell expression vector containing a CMV promoter, using NotI / HindIII, with a signal sequence, a nucleic acid sequence encoding SEQ ID NO: 43-45, and a stop codon. The VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3 sequences of benralizumab and 5R65 used at this time were referenced from the following papers and patents: (Kim et al, 2021) (Republic of Korea Patent Registration No. 10-1973060).

[0265]

[0266]

[0267] For the expression and purification of IL-5Rα(ben)×CD3ε-scFv(L) / scFv-Fc, IL-5Rα(5R65)×CD3ε-scFv(L) / scFv-Fc, and HER2×CD3ε-scFv(L) / scFv-Fc T cell-engaged bispecific antibodies, transient transfection was performed on HEK293F cells (Invitrogen). 1.0×10 HEK293F cells were transfected in 100 mL of a shaker flask. 6Cells were seeded in 90 ml of medium at a density of 10 cells / ml and incubated at 120 rpm, 8% CO2, 37℃. The DNA ratio was 62.5 μg of CH3A (EW), 62.5 μg of CH3B (RVT) (CH3A (EW): CH3B (RVT) = 1:1), so a total of 125 μg of the constructed plasmid was diluted and filtered in 5 ml of serum-free Freestyle 293 expression medium (Invitrogen), mixed with 5 ml of medium in which 375 μg of polyethylenimine (PEI) was diluted, and reacted at room temperature for 10 minutes. After that, the reacted mixed medium was added to the cells seeded in 90 ml previously, and incubated at 120 rpm, 8% CO2, and cultured for 6 days. As a result, the produced protein is secreted outside the cells and accumulates in the medium. Therefore, the protein was purified using a protein A Sepharose column (GE healthcare) from the cell culture supernatant collected by centrifugation at 3800 rpm for 25 minutes after cell culture. At this time, the purification method was referenced to the standard protocol provided by the protein A column company, and the eluted protein was concentrated after exchanging the buffer with 1× PBS using a Vivaspin 30,000 MWCO (Satorius) centrifugal concentrator. The purified protein was measured for absorbance at a wavelength of 562 nm using a solution in the BCA protein assay kit (Thermo), and the amount was quantified according to the drawn standard curve. Table 4 shows the purification yield according to each format. The results were expressed as the standard error of the mean (mean±SD) after performing three independent experiments.

[0268] The physical property evaluation was the same as the process of Example 3, and the results of SDS-PAGE and SEC are shown in Figures 12b and 12c. Through this, it was confirmed that there was no problem in the physical properties of the control T cell-engaged bispecific antibodies of three types of IL-5Rα×CD3ε-scFv(L) / scFv-Fc.

[0269] The following [Table 5] shows the amino acid sequence encoded by the nucleic acid sequence used in the construction of the IL-5Rα(ben)×CD3ε-scFv(L) / scFv-Fc and IL-5Rα(5R65)×CD3ε-scFv(L) / scFv-Fc T cell-engaging bispecific antibodies.

[0270]

[0271]

[0272]

[0273] Example 12: Comparison of receptor binding ability of IL-5Rα(ben)×CD3α-Diabody Fc and IL-5Rα(5R65)×CD3ε-Diabody Fc bispecific antibodies on cell lines expressing IL-5Rα and CD3ε.

[0274] To confirm the binding ability of IL-5Rα(ben)×CD3α-scFv(L) / scFv-Fc, IL-5Rα(5R65)×CD3ε-scFv(L) / scFv-Fc, and HER2×CD3ε-scFv(L) / scFv-Fc, which were constructed as controls for IL-5Rα×CD3ε-scFv(L) / scFv-Fc, to cell surface-expressed receptors, the same experimental method described in Example 7 was used to analyze K562 / IL-5Rα expressing IL-5Rα and activated PBMC expressing CD3 using a FACS Calibur flow cytometer (Flow Cytometry, BD bioscience). (Fig. 13)

[0275] The binding affinities (KD) of 5R65.7, 5R65, and Benralizumab to IL-5Rα reported in the previous literature are 4.64±0.23 nM, 14.5±0.29 nM, and 26.8±0.52 nM, respectively (Kim et al, 2021). The binding patterns for the receptor expressed on the surface of K562 / IL-5Rα cells showed a trend consistent with the binding affinity patterns reported in the literature. Therefore, in the subsequent comparative experiment on the T cell-mediated cytotoxicity induction ability of IL-5Rα×CD3ε-scFv(L) / scFv-Fc and three control antibodies, the differences in biological efficacy were described in terms of binding affinity for the epitope and antigen.

[0276]

[0277] Example 13: Comparison of the T cell-mediated cytotoxicity-inducing abilities of IL-5Rα×CD3α-scFv(L) / scFv-Fc, IL-5Rα(ben)×CD3α-scFv(L) / scFv-Fc, and IL-5Rα(5R65)×CD3ε-scFv(L) / scFv-Fc T cell-engaging bispecific antibodies against K562 / IL-5Rα.

[0278] In order to compare the T cell-mediated cytotoxicity induction ability of the IL-5Rα×CD3α-scFv(L) / scFv-Fc format with the constructed control groups IL-5Rα(ben)×CD3α-scFv(L) / scFv-Fc and IL-5Rα(5R65)×CD3ε-scFv(L) / scFv-Fc, the T cell-mediated cytotoxicity induction ability was compared for K562 / IL-5Rα.

[0279] Specifically, activated PBMCs and target cells (K562 / IL-5Rα, wild-type K562) were used as effector cells and target cells, respectively. 1 x 104 / well of K562 / IL-5Rα cells and IL-5Rα×CD3α-scFv(L) / scFv-Fc, IL-5Rα(ben)×CD3α-scFv(L) / scFv-Fc, IL-5Rα(5R65)×CD3α-scFv(L) / scFv-Fc, HER2×CD3α-scFv(L) / scFv-Fc were diluted to 10 nM, 1 nM, 100 pM, 10 pM, 1 pM, 100 fM, 10 fM, 1 fM, 0.1 fM, and 0.01 fM and dispensed into a U-shaped 96-well cell culture plate. In order to facilitate the T cell response by binding the bispecific antibody to the target cells, the cells were incubated in a CO2 incubator at 37°C for 1 hour. 5 x 10 after that 4 Human PBMCs were dispensed per well. Two wells were cultured for each antibody, and the final volume of each well was prepared to be 150 μl. In order to compare the results under various experimental conditions, i. Effector cell: target cell ratio (E:T ratio) = 5:1, 24-hour culture, ii. E:T ratio = 10:1, 24-hour culture, iii. E:T ratio = 5:1, 12-hour culture conditions were performed. Two hours before harvesting the cell suspension, 15 μl of 10x lysis solution (10x Lysis buffer) was added to the sample to maximize lactate dehydrogenase (LDH) release. After the end of the incubation, 50 μl of cell suspension was collected from each well, and 50 μl of CytoTox96® Reagent (Promega) sample was added and incubated at room temperature for 30 minutes. Add 50 μl of reaction stop solution and measure absorbance using a microplate meter to analyze T cell-mediated cytotoxicity induction. The Y and X axes represent the % maximum cytotoxicity and antibody concentration, respectively.

[0280] Cytotoxicity (%) = (AB) / (CB) × 100

[0281] A: Release value upon antibody treatment

[0282] B: Cell spontaneous release value

[0283] C: Maximum cell release value

[0284] As a result of analyzing the results of conditions i, ii, and iii, the T cell-mediated cytotoxicity induction ability of IL-5Rα×CD3ε-scFv(L) / scFv-Fc against K562 / IL-5Rα was higher than that of IL-5Rα(ben)×CD3ε-scFv(L) / scFv-Fc and IL-5Rα(5R65)×CD3ε-scFv(L) / scFv-Fc, and in particular, the EC50 difference between IL-5Rα(5R65)×CD3ε-scFv(L) / scFv-Fc and IL-5Rα(5R65)×CD3ε-scFv(L) / scFv-Fc was greater than that between IL-5Rα×CD3ε-scFv(L) / scFv-Fc and IL-5Rα(5R65)×CD3ε-scFv(L) / scFv-Fc. It was revealed that the difference in cytotoxicity induction ability between IL-5Rα×CD3ε-scFv(L) / scFv-Fc and IL-5Rα(ben)×CD3ε-scFv(L) / scFv-Fc was mainly due to the difference in epitope between 5R65.7 and benralizumab. This can be confirmed by the quantitative graph (Fig. 14a-Fig. 14c, Table 6-8).

[0285]

[0286]

[0287]

[0288]

[0289] Example 14: Comparison of the T cell-mediated cytotoxicity-inducing abilities of IL-5Rα×CD3α-scFv(L) / scFv-Fc, IL-5Rα(ben)×CD3α-scFv(L) / scFv-Fc, and IL-5Rα(5R65)×CD3ε-scFv(L) / scFv-Fc T cell-engaging bispecific antibodies against eosinophils from healthy donors.

[0290] As a result of evaluating the T cell-mediated cytotoxicity induction ability of IL-5Rα×CD3ε-scFv(L) / scFv-Fc T cell-engaging bispecific antibodies and the control groups IL-5Rα(ben)×CD3ε-scFv(L) / scFv-Fc and IL-5Rα(5R65)×CD3ε-scFv(L) / scFv-Fc for K562 / IL-5Rα, IL-5Rα×CD3ε-scFv(L) / scFv-Fc had the highest binding affinity and targeted the membrane proximal domain, IL-5Rα(5R65)×CD3ε-scFv(L) / scFv-Fc targeted the membrane proximal domain but had a reduced binding affinity, and IL-5Rα(5R65)×CD3ε-scFv(L) / scFv-Fc had the lowest binding affinity and targeted the membrane distal domain. The T cell-mediated cytotoxicity induction ability was highest in the order of IL-5Rα(ben)×CD3ε-scFv(L) / scFv-Fc. Therefore, to determine whether eosinophils could also exhibit this difference in efficacy, the T cell-mediated cytotoxicity induction ability was evaluated using eosinophils as target cells present in the blood of healthy donors and patients with severe asthma.

[0291] Specifically, blood samples from healthy donors and patients with severe asthma were collected to isolate target cells and effector cells. 15 ml of Ficoll-Paque solution (GE Healthcare, 17-5442-03) was dispensed into 50 ml polypropylene centrifuge tubes, and 20 ml of heparinized healthy donor blood was layered onto each tube. The tubes were centrifuged at 750 × g at room temperature for 20 minutes to separate and collect the bottom layer. To remove mixed red blood cells, 1x RBC Lysis buffer (Invitrogen, 00-4300-54), which was diluted 10-fold with 10x RBC Lysis buffer, was dispensed up to 50 ml. The tubes were then centrifuged at 300 × g at 25°C for 10 minutes to separate and collect the layer enriched with granulocytes (eosinophils and neutrophils) from which red blood cells were removed. Finally, eosinophils were purified from granulocytes using a commercially available Eosinophil Cell Isolation Kit (Miltenyi Biotec; 130-092-010) according to the manufacturer's protocol.

[0292] Specifically, autologous activated PBMCs and target cells (eosinophils isolated from the blood of healthy donors and severe asthma patients) were used as effector cells and target cells, respectively, at a ratio of 5:1. 5 x 104 / well of K562 / IL-5Rα cells and IL-5Rα×CD3α-scFv(L) / scFv-Fc, IL-5Rα(ben)×CD3α-scFv(L) / scFv-Fc, IL-5Rα(5R65)×CD3α-scFv(L) / scFv-Fc, HER2×CD3α-scFv(L) / scFv-Fc were diluted to 10 nM, 1 nM, 100 pM, 10 pM, 1 pM, 100 fM, 10 fM, 1 fM, 0.1 fM, and 0.01 fM and dispensed into a U-shaped 96-well cell culture plate. In order to facilitate the T cell response by binding the bispecific antibody to the target cells, the cells were incubated in a CO2 incubator at 37°C for 1 hour. 2.5 x 10 after 5 Activated PBMCs of autologous origin were aliquoted from each well. Human IL-5 was added at a final concentration of 100 pM to ensure minimal eosinophil survival during incubation. Two wells were cultured for each antibody, and the final volume of each well was adjusted to 200 μl. Two hours before harvesting the cell suspension, 15 μl of 10x lysis buffer was added to the sample to maximize lactate dehydrogenase (LDH) release. After the incubation, 50 μl of cell suspension was harvested from each well, and 50 μl of CytoTox96® Reagent (Promega) sample was added and incubated at room temperature for 30 minutes. 50 μl of stop solution was added, and the absorbance was measured using a microplate reader to analyze the T cell-mediated cytotoxicity induction ability. The Y and X axes represent % maximum cytotoxicity and antibody concentration, respectively.

[0293] Cytotoxicity (%) = (AB) / (CB) × 100

[0294] A: Release value upon antibody treatment

[0295] B: Cell spontaneous release value

[0296] C: Maximum cell release value

[0297] The results of evaluating the T cell-mediated cytotoxicity induction ability using a total of five healthy donors and five eosinophils are shown in Figure 15. As a result of T cell-mediated cytotoxicity induction ability for K562 / IL-5Rα cell line, the cytotoxicity induction ability was high in the order of IL-5Rα×CD3α-scFv(L) / scFv-Fc, IL-5Rα(5R65)×CD3α-scFv(L) / scFv-Fc, and IL-5Rα(ben)×CD3α-scFv(L) / scFv-Fc, and the difference in T cell-mediated cytotoxicity induction ability of IL-5Rα×CD3α-scFv(L) / scFv-Fc and IL-5Rα(ben)×CD3α-scFv(L) / scFv-Fc was due to the difference between IL-5Rα(5R65)×CD3α-scFv(L) / scFv-Fc and IL-5Rα(ben)×CD3α-scFv(L) / scFv-Fc. It was confirmed that the difference in the epitope targeted by Benralizumab.

[0298]

[0299] The present invention provides a bispecific antibody comprising an anti-IL-5Rα humanized antibody and an anti-CD3ε humanized antibody, wherein the antibody inhibits the biological activity of IL-5, thereby suppressing the proliferation of patient-derived eosinophils and eliminating eosinophils through T cell mediated cytotoxicity.

[0300] Accordingly, the present invention relates to a bispecific antibody or antigen-binding fragment thereof that binds to IL-5Rα and CD3α, comprising an antibody or antigen-binding fragment thereof that binds to interleukin (IL)-5 receptor α (IL-5Rα) and an antibody or antigen-binding fragment thereof that binds to CD3α.

[0301] The bispecific antibody comprising the anti-IL-5Rα humanized antibody according to the present invention can be used for the prevention or treatment of allergic diseases, inflammatory diseases and / or diseases caused by an increase in eosinophils.

[0302] These diseases include hypereosinophilic syndrome (HES); hypereosinophilia; asthma, including eosinophilic asthma, eosinophilic bronchial asthma (ABA), and severe eosinophilic bronchial asthma (ABA); chronic obstructive pulmonary disease (COPD); Cherge-Strauss syndrome; eosinophilic esophagitis; eosinophilic gastroenteritis; eosinophilic gastrointestinal disease (EGID); atopic diseases, including atopic dermatitis; allergic diseases, including allergic rhinitis; Examples include, but are not limited to, immunoglobulin E (IgE)-mediated food allergies; inflammatory bowel disease, allergic colitis; gastroesophageal reflux disease; endomyocardial fibrosis; Loeffler endocarditis; Davis disease; intermittent angioedema associated with eosinophilia; pseudoeosinophilia-myalgia syndrome / Spanish toxic oil syndrome; cirrhosis; impetigo dermatitis; bullous pemphigoid; Churg-Strauss syndrome; acute myelogenous eosinophilic leukemia; acute lymphocytic eosinophilic leukemia; systemic mast cell disease with eosinophilia; eczema; Wegner's sarcoidosis; polyarteritis nodosa; eosinophilic vasculitis; and rheumatoid arthritis.

[0303]

[0304] While specific aspects of the present invention have been described in detail above, it will be apparent to those skilled in the art that these specific descriptions merely represent preferred embodiments and are not intended to limit the scope of the present invention. Therefore, the substantial scope of the present invention is defined by the appended claims and their equivalents.

[0305]

[0306] Electronic file attached.

Claims

1. A bispecific antibody or antigen-binding fragment thereof that binds to IL-5Rα and CD3α, comprising an antibody or antigen-binding fragment thereof that binds to interleukin (IL)-5 receptor α (IL-5Rα) and an antibody or antigen-binding fragment thereof that binds to CD3α.

2. In the first paragraph, the antibody or antigen-binding fragment thereof that binds to the IL-5Rα comprises a heavy chain CDR1 of SEQ ID NO: 1, a heavy chain CDR2 of SEQ ID NO: 2, a heavy chain CDR3 of SEQ ID NO: 3, and a light chain CDR1 of SEQ ID NO: 4; a light chain CDR2 of SEQ ID NO: 5; a light chain CDR3 of SEQ ID NO: 6; A heavy chain CDR1 of SEQ ID NO: 13, a heavy chain CDR2 of SEQ ID NO: 14, a heavy chain CDR3 of SEQ ID NO: 15, and a light chain CDR1 of SEQ ID NO: 16; a light chain CDR2 of SEQ ID NO: 17; a light chain CDR3 of SEQ ID NO: 18; or Containing a heavy chain CDR1 of SEQ ID NO: 1, a heavy chain CDR2 of SEQ ID NO: 2, a heavy chain CDR3 of SEQ ID NO: 19, and a light chain CDR1 of SEQ ID NO: 4; a light chain CDR2 of SEQ ID NO: 5; and a light chain CDR3 of SEQ ID NO: 6, The antibody or antigen-binding fragment thereof that binds to the CD3α is a bispecific antibody or antigen-binding fragment thereof, comprising a heavy chain CDR1 of SEQ ID NO: 7, a heavy chain CDR2 of SEQ ID NO: 8, a heavy chain CDR3 of SEQ ID NO: 9, and a light chain CDR1 of SEQ ID NO: 10; a light chain CDR2 of SEQ ID NO: 11; and a light chain CDR3 of SEQ ID NO:

12.

3. In the first paragraph, the antibody or antigen-binding fragment thereof that binds to the IL-5Rα comprises a heavy chain variable region of SEQ ID NO: 20 and a light chain variable region of SEQ ID NO: 21, a heavy chain variable region of SEQ ID NO: 22 and a light chain variable region of SEQ ID NO: 23, or a heavy chain variable region of SEQ ID NO: 24 and a light chain variable region of SEQ ID NO:

21. The antibody or antigen-binding fragment thereof that binds to the above CD3α is a bispecific antibody or antigen-binding fragment thereof, comprising a heavy chain variable region of SEQ ID NO: 25 and a light chain variable region of SEQ ID NO:

26.

4. In paragraph 1, a bispecific antibody or antigen-binding fragment thereof comprising at least one selected from the group consisting of: Diabodies of antibodies that bind to IL-5Rα and antibodies that bind to CD3α; scFv antibodies that bind to IL-5Rα and scFv antibodies that bind to CD3α; An antibody comprising a Fab that binds to IL-5Rα and a Fab that binds to CD3α; and BiTE (Bi-specific T-cell engager) binding to IL-5Rα and CD3α and scFv antibody binding to CD3α.

5. A bispecific antibody or antigen-binding fragment thereof, comprising an antibody (immunoglobulin) heavy chain constant region (Fc) pair comprising a first Fc region and a second Fc region, wherein the Fc pair is a heterodimer comprising a mutation in the CH3 domain of the first Fc region or the second Fc region.

6. A bispecific antibody or antigen-binding fragment thereof in which an antibody binds to the N-terminus of the first Fc region or the second Fc region in the fifth paragraph.

7. In paragraph 5, a bispecific antibody or antigen-binding fragment thereof, characterized in that the CH3 domain mutation of the first Fc region or the second Fc region comprises one or more mutations selected from the following group and the mutation position is according to the EU index: (1) Substitution of K360 position in the CH3 domain of the first Fc region with K360E; (2) Substitution of K409W at position K409 in the CH3 domain of the first Fc region; (3) Substitution of E347R at position E347 in the CH3 domain of the second Fc region; and (4) Substitution of F405 position to F405T and substitution of D399 position to D399V in the CH3 domain of the second Fc region.

8. A bispecific antibody or antigen-binding fragment thereof comprising the sequence of SEQ ID NO: 33 to 51 in the first paragraph.

9. A multispecific antibody or antigen-binding fragment thereof comprising the bispecific antibody of any one of claims 1 to 8.

10. A nucleic acid encoding a bispecific antibody or antigen-binding fragment thereof according to any one of claims 1 to 8.

11. An expression vector containing the nucleic acid of Article 10.

12. Cells transformed with the expression vector of Article 11.

13. A method for producing a bispecific antibody or an antigen-binding fragment thereof comprising the following steps: (a) culturing the cells of claim 12 to produce a bispecific antibody or an antigen-binding fragment thereof; and (b) a step of recovering the above bispecific antibody or antigen-binding fragment thereof.

14. A composition for preventing or treating allergic diseases, inflammatory diseases and / or diseases caused by an increase in eosinophils, comprising a bispecific antibody or an antigen-binding fragment thereof according to any one of claims 1 to 8.

15. In claim 14, the allergic disease, inflammatory disease and / or disease caused by an increase in eosinophils is an atopic disease such as hypereosinophilic syndrome (HES); hypereosinophilia; asthma such as eosinophilic asthma, eosinophilic bronchial asthma (ABA) and severe eosinophilic bronchial asthma (ABA); chronic obstructive pulmonary disease (COPD); Cherge-Strauss syndrome; eosinophilic esophagitis; eosinophilic gastroenteritis; eosinophilic gastroenteritis (EGID); atopic dermatitis; Allergic diseases such as allergic rhinitis; food allergies such as immunoglobulin E (IgE)-mediated food allergy; inflammatory bowel disease, allergic colitis; gastroesophageal reflux disease; endomyocardial fibrosis; Loeffler endocarditis; Davis disease; intermittent angioedema associated with eosinophilia; pseudoeosinophilia-myalgia syndrome / Spanish toxic oil syndrome; liver cirrhosis; impetigo dermatitis; bullous pemphigoid; Churg-Strauss syndrome; acute myelogenous eosinophilic leukemia; acute lymphocytic eosinophilic leukemia; systemic mast cell disease with eosinophilia; eczema; Wegner's sarcoidosis; polyarteritis nodosa; eosinophilic vasculitis; rheumatoid arthritis; Kawasaki disease; sickle cell disease; Churg-Strauss syndrome; Grave's disease;A composition characterized in that the disease is selected from the group consisting of pre-eclampsia; Sjogren's syndrome; autoimmune lymphoproliferative syndrome; autoimmune hemolytic anemia; Barrett's esophagus; autoimmune uveitis; tuberculosis; nephropathy; herpes; chronic idiopathic urticaria; scleroderma; hypertrophic scarring; Whipple's disease; benign prostatic hyperplasia; mild; and inflammatory disorders such as inflammatory bowel disease.

16. A composition for removing eosinophils, comprising a bispecific antibody according to any one of claims 1 to 8.

17. A composition according to claim 16, characterized in that it induces cell lysis of eosinophils by engaging T cells with the bispecific antibody.

Citation Information

Patent Citations

  • CH3 domain mutant pairs for the high yield formation of heterodimeric Fc of antibody, method of production and use thereof

    KR101522954B1

  • Antibody against CD3 and pharmaceutical composition for treating cancer comprising the same

    KR101973060B1

  • Antibody Binding to human IL-5Rα and Uses Thereof

    KR1020220035656A

  • CH3 domain variant pair inducing formation of heterodimer of heavy chain constant region of antibody at high efficiency, method for preparing same, and use thereof

    US9951145B2

  • Method, system and non-transitory computer-readable recording medium for providing face-based service

    KR1020220043083A